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Abstract
This thesis considers a variety of statistical issues related to the design and analysis of
clinical trials involving multiple lifetime events. The use of composite endpoints, multi-
variate survival methods with dependent censoring, and recurrent events with dependent
termination are considered. Much of this work is based on problems arising in oncology
research.
Composite endpoints are routinely adopted in multi-center randomized trials designed
to evaluate the effect of experimental interventions in cardiovascular disease, diabetes,
and cancer. Despite their widespread use, relatively little attention has been paid to the
statistical properties of estimators of treatment effect based on composite endpoints. In
Chapter 2 we consider this issue in the context of multivariate models for time to event
data in which copula functions link marginal distributions with a proportional hazards
structure. We then examine the asymptotic and empirical properties of the estimator of
treatment effect arising from a Cox regression model for the time to the first event. We
point out that even when the treatment effect is the same for the component events, the
limiting value of the estimator based on the composite endpoint is usually inconsistent for
this common value. The limiting value is determined by the degree of association between
the events, the stochastic ordering of events, and the censoring distribution. Within the
framework adopted, marginal methods for the analysis of multivariate failure time data
yield consistent estimators of treatment effect and are therefore preferred. We illustrate
the methods by application to a recent asthma study.
While there is considerable potential for more powerful tests of treatment effect when
marginal methods are used, it is possible that problems related to dependent censoring can
arise. This happens when the occurrence of one type of event increases the risk of with-
drawal from a study and hence alters the probability of observing events of other types.
The purpose of Chapter 3 is to formulate a model which reflects this type of mechanism, to
evaluate the effect on the asymptotic and finite sample properties of marginal estimates,
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and to examine the performance of estimators obtained using flexible inverse probabil-
ity weighted marginal estimating equations. Data from a motivating study are used for
illustration.
Clinical trials are often designed to assess the effect of therapeutic interventions on oc-
currence of recurrent events in the presence of a dependent terminal event such as death.
Statistical methods based on multistate analysis have considerable appeal in this setting
since they can incorporate changes in risk with each event occurrence, a dependence be-
tween the recurrent event and the terminal event and event-dependent censoring. To date,
however, there has been limited methodology for the design of trials involving recurrent
and terminal events, and we addresses this in Chapter 4. Based on the asymptotic distri-
bution of regression coefficients from a multiplicative intensity Markov regression model,
we derive sample size formulae to address power requirements for both the recurrent and
terminal event processes. Superiority and non-inferiority trial designs are dealt with. Sim-
ulation studies confirm that the designs satisfy the nominal power requirements in both
settings, and an application to a trial evaluating the effect of a bisphosphonate on skeletal
complications is given for illustration.
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Multivariate failure times are routinely encountered in clinical trials and observational
studies (Hougaard, 2000; Lawless, 2003). In the statistical literature, there have been
several proposed models and methods for the analysis of multivariate failure time data.
These approaches include shared frailty models, copula-based models and robust marginal
methods. In this thesis, we focus on the use of robust marginal methods for the analysis
of multivariate failure time data. With such methods the dependence structure among the
failure times is not modeled directly and inference regarding the regression coefficients is
based on robust variance estimation.
This work is motivated by design and analysis issues in clinical trials. The first stream of
research is motivated by the need to understand the implications of using Cox regression
models for analysis of composite endpoints. In this research we specify models which
are compatible with settings in which composite endpoints are currently thought to be
appropriate. We then study the limiting and finite sample behaviour of resulting estimators
and make recommendations to re-evaluate the current guidelines on the use of composite
endpoints in clinical trials.
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One recommendation from the first study is that marginal methods for multivariate
failure time data be used in settings with multiple correlated event times where it is thought
that there may be proportional hazards between a treatment and control group in the
marginal distributions. This however, motivates the study of the sensitivity of the resulting
estimators to event-dependent censoring mechanisms. This constitutes the second stream
of research.
Finally, there is a need for the development of design criteria for clinical trials involving
multiple lifetime events. The third stream of research involves the development of sample
size criteria for clinical trials aiming to study the effect of a treatment on recurrent events
in the presence of a dependent terminal event. We develop these criteria in the context of a
multistate Markov model incorporating recurrent events through specification of transient
states, and the terminal event through an absorbing state. We consider design of trials
where the objective is to show superiority or non-inferiority with respect to the processes
of interest.
1.2 Use of Composite Endpoints in Clinical Trials
Randomized controlled trials have generated the most useful information on which evidenced-
based medical practice is based. A major decision in the design of a randomized trial is
the selection of the primary endpoint, which plays a central role in the evaluation of the
efficacy of new interventions. In a clinical trial, a primary endpoint is usually a clinical
event chosen on which to base the measure of treatment effect, the test for differences be-
tween arms, and the sample size calculation. An example of a primary endpoint in cancer
clinical trials is time to death (survival). Ideally, the design of a randomized trial should
be based on a single primary endpoint that characterizes the disease in a clinically mean-
ingful way and allows efficient and unbiased assessment of treatment effects. However, in
many diseases, a single primary endpoint may not be sufficient and clinical response can be
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measured in multiple patient outcomes. Investigators have increasingly turned to multiple
endpoints in clinical trials and regulatory agencies are increasingly requiring demonstration
of efficacy for multiple endpoints (Freemantle and Calvert, 2007b; Buzney and Kimball,
2008). Co-primary endpoints have been adopted more often in recent years, and in this
setting two or more endpoints of equal importance are used to characterize the efficacy of
a treatment.
In trials with co-primary endpoints, each endpoint is typically analyzed separately. A
statistical consequence of this design is a possible increase in type I error rate. This mul-
tiplicity issue must be addressed in the study design and analysis plan. One strategy is
“splitting the α” —allocating the 5% type I error unequally across the co-primary end-
points. For example, in a cardiovascular trial with two co-primary endpoints of all-cause
mortality and hospitalization, the all-cause mortality endpoint can be tested at the 0.04
level of significance and the hospitalization endpoint tested at the 0.01 level, thus, pre-
serving the overall 5% type I error rate. A potential advantage of this approach is that
one endpoint may achieve significance whereas the others may not and conclusions can be
drawn accordingly. However, the allocation is usually done in an ad hoc way and there are
few guidelines for optimal allocation depending on importance of each endpoint.
A frequently used strategy for multiple comparisons is the well-known Bonferroni cor-
rection. In this procedure each endpoint is tested at the significance level of α/K, where
α is the overall type I error rate and K is the number of co-primary endpoints. The Bon-
ferroni correction is easy to implement, preserves the overall type error I rate of α, and is
very useful in situations when only one of the endpoints has a non-zero treatment effect.
If the treatment has different effects (i.e., in opposite directions) across the co-primary
endpoints, the interpretation of the treatment effect can be difficult, but there is a clear in-
dication of the nature of the effect. Co-primary endpoints are usually positively correlated
when all relate to efficacy outcomes in which case the Bonferroni correction is conservative.
Composite endpoints (CEP) offer another approach for dealing with multiple endpoints.
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In a composite endpoint, several clinical outcomes of interest are combined into a single
endpoint and each endpoint is considered as a component of the composite endpoint. In-
stead of separate analysis of each endpoint (as in the case of co-primary endpoints), the
event time is the time of the first occurrence of any component endpoint. In general there
are three types of composite endpoints (Chi, 2005). The first type is a total score or index
often encountered in psychotropic studies. The second type of CEP is the occurrence rate
of any events in a CEP after a certain period of follow-up. The third type of CEP is the
time-to-the-first-event. The first two types might be suitable with continuous or binary
responses, respectively, but the third type of CEP is most used in large trials, especially
phase III trials (Chi, 2005). A typical CEP in a cardiovascular disease (CVD) trial may
consist of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death. In this
thesis, we focus on the time-to-the-first-event CEP.
The primary rationale for adopting CEPs in clinical trials is that CEPs may potentially
reduce the required sample size and the duration of trials. Event rates are higher when
including the occurrence of many endpoints in a CEP, which can lead to reduced sample
size for a given level of power and trial duration (Ferreira-González et al., 2007a,b). The
second advantage often credited to a CEP analysis is the ability reflect the net benefit of
treatment—different components in a CEP may represent different aspect of efficacy of the
treatment (Neaton et al., 2005). The third rationale put forward for the use of CEPs is
to avoid the problems of competing risks (Neaton et al., 2005). Patients who have died
cannot experience a non-fatal event of clinical interest. CEPs in CVD trials usually contain
all-cause mortality as a component to account for the competing risk problem. Finally, the
adoption of CEPs may avoid the need to adjust for multiple comparisons by considering
only a single (the first) event.
The use of CEPs in clinical trials is not without controversies, and there are several
disadvantages of CEPs discussed in the medical literature. The most frequently attributed
disadvantage of CEPs is that of heterogeneity. There are two types of heterogeneity in
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CEPs (Ferreira-González et al., 2008). First, the treatment effect may be different across
the components and second, the clinical importance of component endpoints may be very
different. When the component endpoints in a CEP are of different clinical importance, the
interpretation of the treatment effect from a CEP analysis can be misleading if the overall
positive result driven by a treatment effect on a less important endpoint. Moreover, if the
magnitude of the treatment effect on components are very different, the interpretation is
problematic as well. From a statistical point of view, the inclusion of a component with
little or no treatment effect can dilute the evidence of a treatment effect and hence may
lead to reduced power when testing the efficacy of treatment.
Three key recommendations have been proposed in the medical literature to provide
guidelines for proper use of CEPs in clinical trials (Montori et al., 2005). The first recom-
mendation is that each component in a CEP should be of the same clinical importance.
The second is that each component should have equal frequencies of occurrence. The third
is that the treatment effect on each component should be roughly equal. The first recom-
mendation is purely from a clinical point of view and can facilitate the interpretation of
the treatment effect on the composite endpoint. The second and third recommendations
are motivated in part by statistical considerations. These three recommendations are cur-
rently actively discussed in the medical literature. We examine them from a statistical
perspective in Chapter 2 of this thesis.
1.3 Methods for Multivariate Failure Time Data
Since co-primary endpoints are often positively correlated failure times, the analysis of co-
primary endpoints often requires models and methods for multivariate failure time data.
In this section, we review some commonly used models and methods. We consider the case
where none of these events are fatal and so we do not have to deal with a competing risk
problem. Suppose that there are K such different types of events. Let Ti1, ..., TiK denote
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the random variables of the event times for the K types of events. In general there could be
different censoring times Ci1, ..., CiK for the different events times, but usually a common
censoring time is used and we set Cik = Ci, and therefore observe Xik = min(Tik, Ci),
k = 1, ..., K. Let zik denote a pk × 1 covariate vector for a regression model for Tik. We
are typically concerned with methods for estimation and inference which addresses the
association between the failure times and hence yield valid inferences. In some contexts
we may be interested in joint probability statements and sometimes we are interested
in the association between event times. One convenient way of generating multivariate
distributions is through random effects models. These are used widely for dealing with
clustered and longitudinal data with generalized linear models. We consider this approach
in the next section.
1.3.1 Frailty Models
Consider a conditional hazard for event time k, given by
lim
∆t→0
P (t ≤ Tik < t+ ∆t|uik, zik)
∆t
= uikh0k(t;αk) exp(zikβk)
where uik is a random effect independent of zik, with mean 1 and variance φk . Here
h0k(t) is the (conditional) baseline hazard function and βk the covariate effects for the
type k events. In the context of survival data, random effects are often called “frailty
parameters” or “frailties” since they can often be interpreted as characterizing the frailty,
or risk, a particular individual has compared to the average member of the population with
the same covariate vector. In studies of aging the more frail individuals are the greater
risk of death, for example. We may think of multivariate frailties and so think of a vector
ui = (ui1, . . . , uiK)
′ where cov(uik, uil) = φkl accommodates an association between failure
times within individuals. While this is appealing in its generality it can be computationally
challenging to work with such models.
A much simpler model is obtained if we consider a common frailty and set uik = ui, k =
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1, . . . , K, with E(ui) = 1 and var(ui) = φ. If α = (α1, . . . , αK)
′, β = (β1, . . . , βK)
′, zi =
(zi1, . . . , ziK)
′, and ui and zi are independent, then since
P (Tik > tk|zi, ui) = exp(−uiH0k(tk, αk) exp(zikβk)),
we have
















where Fik(tk|ui, zik;αk, βk) = exp(−
∫ tk
0
uih0k(s;αk) exp(zikβk)ds) is the conditional sur-
vivor function for type-k events. A number of distributions for ui can be adopted but we
will consider here the gamma distribution for analytical tractability, in which case
































The joint density for (Ti1, . . . , TiK |zi) can be obtained by differentiation of the joint survival
distribution.
The frailty model accommodates an association between the survival time Ti, but it
may not lead to very appealing covariance structures. In regression models with covariates,
the covariance structures induced by the frailty model becomes more complicated and the
association depends on the covariate values for the pairs of failure times under considera-
tion. Moreover, even though frailty models can be based on a proportional hazards models
conditionally on a random effect, this will not yield a proportional hazards model after
marginalizing over the frailty parameter. To see this, consider the marginal gamma frailty
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model, where the frailty has a gamma distribution. Hence










This does not have the proportional hazards form.
When the covariate effects on the marginal hazard do not have a constant relative risk
form, this can cause difficulties in interpretation of the treatment effect. This arises because
the frailty induces both dependence and heterogeneity into the model (Liang et al., 1995).
1.3.2 Copula Models
The frailty approach for dealing with clustered or multivariate data is convenient but as
stated earlier there can be problematic features of the resulting dependencies and the fact
that the covariate effects are not expressed in proportional hazards forms in the marginal
distributions can be undesirable. Copula models offer an alternative approach for modeling
association between failure time, which until relatively recently, were not used extensively
in applications. They have the appealing property of linking two marginal distributions
and so marginal features may be constructed in any desirable way. Specifically, we can
model the marginal distribution of Tk through the Cox proportional hazards model where
for the ith subject
λk(t|zik) = λ0k(t) exp(zikβk).
This hazard function fully specifies the marginal survival function Sk(t|zik) for the Tik.
Note also that Sk(Tik|zik) is distributed as a uniform (0, 1) random variable. The joint dis-
tribution of Ti1, . . . , TiK and hence the dependence structure among them can be modelled
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as
S(t1, . . . , t2|zi) = P (Ti1 > t1, . . . , TiK > tK |zi)
= C(S1(t1|zi1), . . . , SK(tK |ziK),Θ),
where C(·) is a K variate distribution function indexed by the parameter φ with uniform
(0, 1) margins. The function C is known as the copula function and different choices of C
can lead to a different joint survival distribution of T1, . . . , TK while preserving the same
marginal distributions. One noticeable advantage of copula models is that the interpreta-
tion of the regression coefficient is the same regardless the choice for C. If the margins
involve Cox models the coefficients have the usual interpretation and yield constant hazard
ratios; that is the proportional hazard assumption always holds for margins in a copula
model if this framework is adopted for the margins. The parameter Θ in copula functions
usually measures the degree of correlation, and the Kendall’s tau, usually a function of Θ,
is often adopted as the measure of dependence.
A commonly used family of copula function is the Archimedean copulas,




where gφ is a function mapping from (0,∞) to (0, 1) such that gφ(0) = 1, g
′
φ(t) < 0 and
g
′′
φ(t) > 0 for all t ∈ [0,∞). In particular, if gφ is a Laplace transform of a random variable
with cumulative distribution of Gφ, the above expression is




where g−1 is the inverse Laplace transformation (Nelsen, 2006).
The Archimedean copulas with Laplace transformations represent a large family of
copulas often used in survival analysis. For example, the Laplace transformation of a
gamma distribution yields the well known Clayton copula. The Gumbel-Houguaard copula
and the Frank copula also belong to the Archimedean copula family.
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There are some disadvantages of copula modeling in the analysis of multivariate failure
time data. The specification of suitable copula model can be challenging and goodness-fit
tests for choosing a particular type of copula model are still an area of active research.
It seems to be a simple task to construct the likelihood for inference purposes once the
copula model is specified, however if the margins are semiparametric regression models,
the likelihood function based on copula will be complicated and estimation computation-
ally intensive. Two-stage pseudo-likelihood methods have been proposed in the literature
(Liang et al., 1995). At stage one, the estimation proceeds for the marginal parameters
under the assumption that the failure times are independent; estimates of the regression
coefficients and the baseline hazard functions are thus obtained. At the second stage, these
estimates are plugged into the likelihood function based on the joint model to make infer-
ence for φ based on a so-called the pseudo-likelihood for φ. While there is a possible slight
loss of efficiency of this two-stage pseudo-likelihood method relative to the full likelihood
approach, the computational advantages are attractive.
1.3.3 Robust Marginal Methods
One possible extension of the Cox regression model for dealing with multivariate failure
time data is the marginal approach of Wei, Lin and Weissfeld (1989), referred to as the
WLW approach. The WLW approach is similar to the two-stage approach for the copula
model in that marginal proportional hazards analyses are performed by each marginal fail-
ure times Ti1, . . . , TiK , as if they are independent. At the second stage, a robust covariance
estimator is obtained to account for possible correlation between the estimators of the re-
gression coefficients. The WLW approach is well-suited for multivariate failure time data,
where each patient is at the risk of and may experience several failure types in clinical
trials.
Since marginal analyses are planned, counting processes need to be specified for each
event type and we explore this more fully here. Subjects are considered at risk for each
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event from the time of first contact. Let Ci be a right censoring time, then Yi(t) = I(t ≤ Ci)
indicates whether subject i is under observation at time t. We observe Xik = min(Tik, Ci)
and δik = I(Xik = Tik). Then let Y
M
ik (t) = I(t ≤ Tik) be the “at risk” indicators for
the marginal analyses of type k events. Then Ȳ Mik (t) = Yi(t)Y
M
ik (t) = 1 if the ith subject
is under observation and has not yet experienced the type k event at time t. We let
dNik(t) = 1 if the type k event for subject i occurs at time t and dNik(t) = 0 otherwise,
and we let dN̄ik(t) = Ȳ
M
ik (t)dNik(t) indicate the type k event occurred and was observed at
time t. Let zi = 1 if subject i is randomized to the treatment group and zi = 0 otherwise.







−)−Nik(t−) = 1|Nik(t−) = 0, zi = 0)
∆t
is the crude hazard function defined by omitting information on any possible earlier events




−)− N̄ik(t−) = 1|N̄ik(t−) = 0, Ȳ Mik (t) = 1, zi = 0)
∆t
denote the marginal hazard for the observable event process. If we assume independent
censoring and the same treatment effect for each marginal model, the “marginal” hazard
becomes

























given a dataset of size m. The estimating equation for a common β is based on the score
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j exp(zjβ), r = 0, 1 for the WLW estimate with a com-
mon regression coefficient. In this case the regression coefficient has the interpretation
as the common treatment effect for all event types. The above model can be changed to
incorporate different regression coefficients for each event type through separate models




k0(t) exp(ziβk), k = 1, 2, . . . , K. A stratified maximum partial likelihood
can be used to obtain the estimates of regression coefficients. Since no overall likelihood
is assumed for the joint distribution of the K type events, the WLW approach next in-
volves computing a robust variance estimator to account for the possible correlation among
the estimates of the regression coefficients and ensure control of frequency properties for
simultaneous inferences regarding β = (β1, . . . , βK)
′.
If different regression coefficients are accommodated for different events, the regression
coefficients β = (β1, . . . , βK)
′ are estimated by solving the pseudo-likelihood score equations























k exp(zkβk), r = 0, 1, k = 1, . . . , K. These pseudo-score equa-
tions are similar to score equations for a ordinary univariate Cox model. Marginally, the
existence, uniqueness, and consistency of the maximum partial likelihood estimator β̂k and
−m−1∂Uk(βk)/∂βk|βk=β̂k for E(∂U(βk)/∂βk)|βk=βok , (where β
o
k is the true value), follows
















(dN̄ik(t)− Ȳ Mik (t)αMk0(t) exp(ziβo)),













k) ∼ N(0, Bk(βok)), where Bk(βok) = E(wk(βok)2). It follows from the
multivariate central limit theorem that, asymptotically, m1/2(β̂−βo) ∼MVN(0,D(βo)),





I(·) is a diagonal matrix with the kth element in the diagonal is E(∂U(βk)/∂βk)|βk=βok .
Both B(·) and I(·) can be consistently estimated from the data (Wei et al., 1989) and the
existing software such SAS and R can be used to obtain those estimates to calculate the
variance of estimators of regression coefficients for a broad range of models.
Suppose that we want to test the hypothesis H0 : β = 0. It is possible to carry out
omnibus K degree of freedom tests but more narrowly focused tests optimized to detect
treatment effects which are in the same direction for all events are typically more powerful
for detecting departures from the null hypothesis of interest. To this end, let J = (1, . . . , 1)
denote a K × 1 vector of ones. Let H = (J ′B̂
−1
(0)J)−1 × J ′B̂
−1





and therefore large realized values of V (0) reflect the evidence against H0. If estimation
of a common treatment effect βoc is of interest, a pooled estimate of the treatment effects





(β̂)β̂ for which m1/2(β̂c − βoc )
is asymptotically normal with mean zero and variance (J ′D̂
−1
(β̂)J)−1 . The weights in
this pooled estimator provide minimum variance within the class of estimators obtained
through linear combination.
1.4 Recurrent Events with Terminal Events
Recurrent events, such as repeated tumour occurrences, infections, hospital admissions,
and multiple rejection episodes after organ transplant, are routinely encountered in clinical
and observational studies (Cook and Lawless, 2007). The observation of recurrent events
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could be disrupted by loss to follow-up, administrative censoring, or a terminal event such
as death. Analysis is usually focused either on the failure time using standard survival
analysis, or, the recurrent event process using semiparametric methods based on rate or
mean functions. In many settings, the terminal events may be of interest in conjunction
with recurrent events. For example, the recurrence of serious events such as tumours is
associated with an increased risk of death. Analyzing the data based on recurrent events
or terminal event alone may lead to an incomplete picture. Therefore, it is important to
take into account both terminal events and recurrent events.
There have been relatively extensive discussions in the literature on statistical analysis
of recurrent event data. Andersen and Gill (1982) and Prentice et al. (1981) developed
intensity-based methods for univariate recurrent event data. Lawless and Nadeau (1995),
Lin et al. (2000, 2001) proposed methods based on marginal mean function and rate
function approaches. Cai and Schaubel (2004), for example, investigated methods for the
analysis of multivariate recurrent event data.
Some efforts have been made in recent years on modeling the recurrent events and the
terminal events. Li and Lagakos (1997) proposed a marginal approach of based on Wei,
Lin and Weissfeld (1989). Ghosh and Lin (2003) proposed a joint marginal formulation for
the distributions of the recurrent event process and dependent censoring time. Chen and
Cook (2004) proposed methods for multivariate recurrent event data with some common
dependent terminal event. Joint assessment of the treatment effect on the recurrent events
and death has been discussed previously using log-rank type of statistics, for example, see
Cook and Lawless (1997) and Ghosh and Lin (2000). Other methods for joint analysis of
recurrent events and terminal events include shared frailty models, partially conditional
methods, and so forth. Cook and Lawless (2007) contains a comprehensive review of
methods and models for recurrent events with terminal event.
Sample size calculations are very important in the design of clinical trials. In the
recurrent event setting, Cook (1995) proposed a sample size calculation using a nonho-
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Figure 1.1: State space diagram for recurrent and terminal events representing the model
formation based on counting processes; λ0k(t)e
zβk , k = 0, 1, 2, . . ., are transitional
intensities for the recurrent events from state k to state k + 1, where state D represents
the terminal event of death. γ0k(t)e
zαk , k = 0, 1, . . ., are the mortality rates dependant on
the event history.
mogeneous Poisson process. Bernardo and Harrington (2001) discussed power and sample
size calculations using a multiplicative intensity model. Hughes (1997) considered a sample
size calculation for the marginal approach of WLW. Few studies, however, have considered
power and sample size calculations for recurrent events with a terminal event. One objec-
tive of this thesis is to derive a score statistic for such a purpose, along with sample size
guidelines.
We focus on intensity-based approaches and review some notation and likelihood con-
struction for recurrent events with terminal events based on Cook and Lawless (2007). This
review will be helpful in the calculation of the sample size. Let ∆Ni(t) denote the number
of recurrent events over the small interval [t, t + ∆t) and dNi(t) = lim
∆t↓0
∆Ni(t). Let Ci be
the censoring time corresponding to the end of follow-up and let Yi(t) = I(t ≤ Ci). If Ti is
the terminal event time for subject i, let Y Di (t) = I(t ≤ Ti). Then Ȳi(t) = Yi(t)Y Di (t) is the





H̄i(t) = {(N̄i(s), Ȳi(s)) : 0 ≤ s < t} be the process history up to time t and a full model for
the process can be formulated in terms of the intensity functions for the recurrent event
process λi(t|H̄i(t)) and the terminal event process γi(t|H̄i(t)) defined as,
λ(t|H̄i(t)) = lim
∆t↓0




P (Ti < t+ ∆t|H̄i(t), Di(t) = 1)
∆t
,
respectively. The history H̄i(t) in intensity functions can also incorporate covariate pro-
cesses. Figure 1.1 presents a general Markov model for recurrent events and a terminal
event. Here we assume a multiplicative model on transition intensity and allow differ-
ent baseline hazard functions and treatment effect to be incorporated into the intensity
function.
We now discuss the likelihood construction. Let ni be the number of recurrent events
of subject i observed at times ti1, . . . , tini over [0, Xi] where Xi = min(Ti, Ci), then under







and δi = I(Ti = Xi). This likelihood provides the basis for our derivation of power
and sample size calculations for recurrent events with terminal event, for any particular
specification of the intensities. We explore them in Chapter 4.
1.5 Outline of Research
Despite the routine use of composite endpoint in large clinical trials, there has been rela-
tively little attention paid to the statistical properties of associated estimation of treatment
effect. In Chapter 2, we focus on the implications of using Cox regression model in anal-
ysis of composite endpoints with failure time components. We formulate multivariate
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survival models by linking two marginal failure time distributions with proportional haz-
ards through a copula function. We showed that the proportional hazard assumption of
Cox regression model for the time-to-first-event is generally violated by the design of CEP,
even when the same assumption holds for each components. We also use simulations to
further study the treatment effect estimation in CEP analysis and its implications in sam-
ple size requirement and power. We proposed a global design using the WLW approach
and compare its performance with that of a CEP analysis. We illustrate the methods by
application to a recent asthma study.
In Chapter 3 we continue to study marginal approaches for multivariate failure times.
We consider methods based on marginal rate and mean functions for event times. In
particular, we developed an inverse probability of censoring weighted (IPCW) versions
of WLW to provide a global treatment effect estimate in presence of event-dependent
censoring. Event-dependent censoring can occur in multivariate failure time analysis. The
occurrence of sever type event may lead to early exclusion of the patient from the study.
Failure to account for the event-dependent censoring can lead to bias in estimation in
marginal approach and IPCW-based methods provide consistent estimates (Kang and Cai,
2009).
Sample size calculations are extremely important in designs of clinical trials. There
have been some discussions on sample size and power calculations for multivariate failure
times, but there has been few studies on sample size calculations for recurrent events with
terminal event. In Chapter 4, we derive ways to calculate sample size for clinical trials
involving recurrent and terminal events. The key idea is to derive the expectation of a
partial score function for a treatment effect on the recurrent and terminal event processes
and the respective asymptotic variances. One may then design trials to satisfy power
objectives for both types of events. This is particularly useful when there may be an




Cox Regression With Composite
Endpoints
2.1 Composite Endpoints in Clinical Trials
Many diseases put individuals at elevated risk for a multitude of adverse clinical events and
randomized clinical trials are routinely designed to evaluate the effectiveness of experimen-
tal interventions for the prevention of these events. Trials in cardiology, for example, record
times of events such as non-fatal myocardial infarction, non-fatal cardiac arrest, and car-
diovascular death (POISE Study Group, 2008). In cerebrovascular disease, patients with
carotid stenosis may can be treated with medical therapy or surgery and trials evaluating
their relative effectiveness may record endpoints such as strokes ipsilateral to the surgical
site, contralateral strokes, and death (Bartnett et al., 1998). In oncology, trials are often
designed to study treatment effects on disease progression and death (Carlson, 2007), but
palliative trials of patients with skeletal metastases may be directed at preventing skele-
tal complications including vertebral and non-vertebral fractures, bone pain, and need for
surgery to repair bone (Hortobagyi et al., 1996). In these and many other settings, while
interest lies in preventing each of the respective events, it is generally infeasible to conduct
18
studies to answer questions about each component.
When one type of event is of greater clinical important than others, it can be chosen
as the basis of the primary treatment comparison, and effects on other types of events can
then be assessed through secondary analyses. When two or more events are of comparable
importance, co-primary endpoints can be specified but tests of hypotheses must typically
control the experimental type I error rate through multiple comparison procedures (Be-
jamini and Hochberg, 1995; Sankoh et al., 2003; Proschan and Waclawiw, 2000), but these
make decision analyses more complex. A seemingly simple alternative strategy is to adopt
a so-called composite event (Ferreira-González et al., 2007c; Cannon, 1997) which is said
to have occurred if any one of a set of component events occurs. The time of the composite
event is therefore the minimum of the times of all component events.
There are several additional reasons investigators may consider the use of composite
endpoints in clinical trials. In studies involving a time-to-event analysis, the use of a
composite endpoint will mean that more events will be observed than would be for any
particular component. If the same clinically important effect is specified for the composite
endpoint and one of its components, this increased event rate will translate into greater
power for tests of treatment effects; at the design stage a reduction in the required number
of subjects or duration of follow-up (Cannon, 1997; Freemantle et al., 2003; Montori et al.,
2005). This rationale presumes that the same minimal clinically important effect applies
for the composite endpoint and the component endpoint of interest. Composite endpoints
are routinely adopted through the introduction of one or more less serious events, which
presumably warrants changing the clinically important effect of interest. Moreover we show
later that with models featuring a high degree of structure, model assumptions may not
even be compatible for the composite endpoint and one of its components.
In time-to-event analyses, interest may lie in the effect of an experimental treatment
versus standard care on the risk of a non-fatal event. This is a common framework in
trials of patients with advanced diseases where interest lies in improving quality of life
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through the prevention of complications. In such settings individuals are at considerable
risk of death, and a competing risks problem arises. Investigators often deal with this by
adopting a composite endpoint based on the time to the minimum of the non-fatal event of
interest and death (Chi, 2005; Ferreira-González et al., 2007b). This strategy leads to an
“event-free survival” analysis which is particularly common in cancer where progression-
free survival is routinely adopted as a primary endpoint (Soria et al., 2010). In palliative
trials, a treatment may not be expected to have an effect of survival, and if a non-negligible
proportion of individuals die before experiencing the clinical event of interest, this analysis
can lead to a serious underestimation of the effect of the treatment (Freemantle et al.,
2003; DeMets and Califf, 2002).
Recommendations are available in the literature on how to design trials, analyse re-
sultant data, and report findings when composite endpoints are to be used (Freemantle
et al., 2003; Montori et al., 2005; Chi, 2005; Neaton et al., 2005). The main recommenda-
tions include that i) individual components should have similar frequency of occurrence,
ii) the treatment should have a similar effect on all components, iii) individual components
should have similar importance to patients, iv) data from all components should be col-
lected until the end of trial, and v) individual components should be analyzed and reported
separately as secondary endpoints. The first three recommendations have face validity and
seem geared towards helping ensure that conclusions regarding treatment effects on the
composite endpoint have some relation to treatment effects on the component endpoints,
thus helping in the interpretation of results. The collection of data on the occurrence of the
component endpoints until the end of the trial facilitates separate assessment of treatment
effects on each of the component endpoints. This means the consistency of findings across
components can be empirically assessed.
The aforementioned challenges have being actively debated in the medical literature
(Montori et al., 2005; Neaton et al., 2005; Lim et al., 2008; Ferreira-González et al., 2007a;
Bethel et al., 2008), but there has been relatively little formal statistical investigation of
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these issues. In this Chapter we consider statistical issues related to composite endpoint
analyses and use the recommendations to guide the investigation. Since the Cox regression
model is routinely adopted for the analysis of composite endpoints in clinical trials (Chi,
2005), we consider it here and point out important issues regarding model specification and
interpretation. We formulate multivariate failure time models with proportional hazards
for the marginal distributions which may be used to reflect the settings where composite
endpoints are most reasonable according to the current guidelines. We study the asymp-
totic and empirical properties of estimators arising from a composite endpoint analysis. We
also explore the utility of marginal methods based on multivariate failure time data (Wei
et al., 1989). We will argue in what follows that the viewpoint that composite endpoints
provide an overall measure of the effect of treatment is overly simplistic, and a thoughtful
interpretation of intervention effects based on composite endpoints alone is difficult.
2.2 Multivariate Failure Time Distributions via Cop-
ula Functions
2.2.1 Construction of Joint Distributions based on Copula Func-
tions
If (U1, U2)
′ is a bivariate random variable with standard uniform margins on [0, 1], a two-
dimensional copula function can be defined as
C(u1, u2) = P (U1 ≥ u1, U2 ≥ u2) , (2.1)
(Genest and Mackay, 1986). If there exists a convex decreasing function H(u; θ) such that
H : (0, 1]→ [0,∞) and H(1; θ) = 0, and if the copula function can be written as
C(u1, u2; θ) = H−1(H(u1; θ) +H(u2; θ); θ) ,
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then copula belongs to the Archimedean family of copulas; the univariate function H(u; θ)
is called the generator for the copula Nelsen (2006). A variety of measures of association
can be defined for U1 and U2 which are determined as the functions θ. For example, suppose
(Ui1, Ui2)
′ and (Uj1, Uj2)
′ are two random variables drawn from the joint distribution (2.1).
A common measure of the association between U1 and U2 is Kendall’s τ , defined as
τθ = P{((Ui1 − Uj1)(Ui2 − Uj2); θ) > 0} − P{((Ui1 − Uj1)(Ui2 − Uj2); θ) < 0} .
For Archimedean copulas this can be written as






where we write τθ to make the relation between θ and τ explicit.
Copula functions have received considerable attention in the statistical literature in the
past few years since they offer a convenient and attractive way of linking two marginal
distributions to create a joint survival function (Joe, 1997). Suppose T1 and T2 are a
pair of non-negative random variables with respective survivor functions F1(t1|z;α1) and
F2(t2|z;α2) given a covariate z. If we let U1 = F1(T1|z;α1) and U2 = F2(T2|z;α2) where αk
indexes the marginal distribution for Tk|z, then Uk ∼ UNIF(0, 1), k = 1, 2. We can define
the bivariate “survival” distribution function of (U1, U2) through a copula as in (2.1) and
obtain a joint survivor function for (T1, T2)
′ given Z as
F12(t1, t2|z; Ω) = P (T1 ≥ t1, T2 ≥ t2|z; Ω) = Cθ(F1(t1|z;α1),F2(t2|z;α2); θ) , (2.2)
where Ω = (α′, θ)′ with α = (α′1, α
′
2)
′. Because Kendall’s τ is invariant to monotonic
increasing or decreasing transformations (Genest and Mackay, 1986), it can be interpreted
as a measure of association of the transformed variables (T1, T2)
′ given Z. The use of a
copula function to define the joint distribution of (T1, T2)|z is particularly appealing since
one can specify the marginal distributions to have a proportional hazards form; this is
not typically possible for joint distributions induced by random effects or intensity-based
analyses.
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If a composite endpoint analysis is planned it would be based on modeling the random
variable T = min(T1, T2), which has survival, density and hazard function conditional on
Z, give by
P (T ≥ t|z) = F(t|z; Ω) = F12(t, t|z; Ω) , (2.3)
f(t|z) = −dF(t|z; Ω)/dt and λ(t|z; Ω) = −d logF(t|x; Ω)/dt respectively. Suppose Z is a
binary indicator where Z = 1 for individuals in a treatment group and Z = 0 otherwise. A
key point is that the hazard ratio λ(t|z = 1; Ω)/λ(t|z = 0; Ω) is not, in general, independent
of time. As a result, even if the marginal distributions feature the proportional hazards
assumption, the model for the composite endpoint will typically not. We study this point
further in the next four settings for three different Archimedean copulas and the case of
independent components.
Composite Endpoint Analysis based on a Clayton Copula:
The Clayton copula (Clayton, 1978) is a member of the Archimedean family with generator
H(u; θ) = u−θ − 1, H−1(v; θ) = (v + 1)−1/θ and copula function







with θ ≥ −1. Kendall’s τ is then given by τθ = θ/(θ + 2), which can be seen to vary over
[−1, 1].
Consider the joint distribution of (T1, T2)|Z in which the marginal distributions for
Tk|Z, k = 1, 2, feature proportional hazards; so λk(t|z) = λk0(t) exp(βkz) with Λk(t|z) =
Λk0(t) exp(βkz) where Λk0(t) =
∫ t
0
λk0(s)ds, k = 1, 2. If the joint survivor function
F12(t1, t2|z; Ω) is determined by the Clayton copula through (2.2), by (2.3) the survivor
function of the failure time T = min(T1, T2) given z is
F(t|z; Ω) = [exp(θΛ10(t)eβ1z) + exp(θΛ20(t)eβ2z)− 1]−1/θ . (2.5)
Hence the hazard ratio for the treatment versus control groups for the composite endpoint
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is
λ(t|z = 1; Ω)















which is not invariant with respect to time in general. Note that this ratio is 1 when
β1 = β2.
To gain some insight into this function, suppose the marginal distributions are ex-
ponential with common baseline hazards of λ10(t) = λ20(t) = λ = log 10 so that the
probability of a type k event occurring before t = 1 is 0.90 for a control subject (i.e.
P (Tk < 1|Z = 0) = 0.90). Further suppose a common hazard ratio of 0.50 holds for the two
margins (i.e. exp(β1) = exp(β2) = 0.50). This setting is consistent with the recommenda-
tions that the component events occur with comparable frequency since P (T1 < T2|Z) = 0.5
and have comparable treatment effects (β1 = β2). Figure 2.1 (a) contains a plot of the
hazard ratio (2.6) over the time interval [0, 1] for models with mild (τθ = 0.2), moderate
(τθ = 0.40), and strong (τθ = 0.60) association. As can be seen, even when the treatment
effects are the same for the two component endpoints, there can be non-negligible variation
in the hazard ratio over time, and within this family of models the nature of this variation
depends on the strength of the association between the two failure times.
Composite Endpoint Analysis based on a Frank Copula
The generator for the Frank copula (Genest, 1987) isH(u; θ) = − log((exp(−θt)−1)/(exp(θ)−
1)) and the resulting copula function is
C(u1, u2; θ) = −θ−1 log
[
1 +




where θ ∈ <; Kendall’s τ is then τθ = 1− 4θ−1 + 4θ−2
∫ θ
0
t/(exp(t)− 1)dt. If we adopt the





















































Figure 2.1: Plots of the hazard ratio (treatment vs. control) over the time interval [0, 1]
for the composite endpoint analysis implied by the Clayton copula (Panel (a)) and Frank
copula (Panel (b)) with marginal exponential distributions with λ1 = λ2 = log 10 and
exp(β1) = exp(β2) = exp(β) = 0.50, and mild (τθ = 0.20), moderate (τθ = 0.40), and
strong (τθ = 0.60) association.
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but since λ(t|z; Ω) = −d logF(t)/dt, the hazard ratio λ(t|z = 1; Ω)/λ(t|z = 0; Ω) has a
complicated form. Figure 2.1 (b) contains a plot of this hazard ratio over [0, 1], and as in
the case of the Clayton copula there is considerable variation in this ratio over time.
Composite Endpoint Analysis based on a Gumbel-Hougaard Copula:
The generator for the Gumbel-Hougaard (Gumbel, 1960) copula is H(u; θ) = (− log t)θ
giving
C(u1, u2; θ) = exp(−((− log u1)θ + (− log u2)θ)θ
−1
) ,
for θ ≥ 1; Kendall’s τ is given by τθ = (θ − 1)/θ. The corresponding survivor function for
























Interestingly, the hazard ratio in this case is exp(β), which means that the proportional
hazards model for the composite endpoint is compatible with a proportional hazards model
for the margins. If the hazard ratio is in fact common for the component endpoints then
a consistent estimator will be obtained for this common effect based on a Cox model for
the composite endpoint.
Composite Endpoint Analysis with Independent Components:
Here we consider the setting where the component failure times are independent; a special
case of τθ = 0 for the joint models in Section 2.2.1. In this case the hazard ratio for the








It is apparent that the composite endpoint analysis is only compatible with a proportional
hazards assumption if either
A.1) β1 = β2 = β, (2.7)
or
A.2) λ10(t) = λ20(t). (2.8)
If β1 = β2 = β, then a consistent estimate of this common effect is obtained in a
composite endpoint analysis. If β1 6= β2 but the hazard functions are identical, the multi-
plicative effect is (exp(β1)+exp(β2))/2. If assumptions A.1 (2.7) and A.2 (2.8) do not hold
then the ratio is a complicated time varying function of the baseline hazards and respective
treatment effects.
2.2.2 Misspecification of the Cox Model with Composite End-
points
The previous section demonstrated that the composite endpoint analysis is typically based
on a misspecified Cox regression model if the marginal distributions satisfy the proportional
hazards assumption. In this section we investigate the frequency properties of estimators
from a composite endpoint analysis when the component endpoints are associated through
a copula function.
Let Ti = min(Ti1, Ti2) denote the time of the composite endpoint for individual i in
a sample of size m. Let {Ni(s), s < 0} denote the counting process for subject i which
indicates the occurrence of the composite endpoint, so that dNi(s) = 1 if Ti = s and is zero
otherwise. Suppose it is planned to follow all subjects over the interval (0, C†], but that
subjects may be lost to follow-up or withdraw from the study prematurely. LetWi represent
the withdrawal time for subject i and Ci = min(Wi, C
†) denote their right censoring time.
Let Yi(s) = I(s ≤ Ti) indicate whether subject i is at risk of the composite endpoint at time
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s, Y †i (s) = I(s ≤ Ci) indicate whether they are under observation at time s, and Ȳi(s) =
Y †i (s)Yi(s) indicate whether they are event-free and under observation. The observable
counting process for the response is then based on dN̄i(s) = Ȳi(s)dNi(s) for subject i. The
data for a sample of size m then consist of {Ȳi(s), dN̄i(s), Zi, i = 1, . . . ,m} which, if we
let Ȳ (s) = (Ȳ1(s), . . . , Ȳm(s))
′, dN̄(s) = (dN̄1(s), . . . , dN̄m(s))
′ and Z = (Z1, . . . , Zm)
′, we
may write more compactly as {Ȳ (s), dN̄(s), Z}.
The Cox model is widely used in the analysis of composite endpoints Cox (1972) to
estimate the relative hazard for events. In this case the hazard function for Ti|zi is assumed
to have the form
ψ(t|zi) = ψ0(t) exp(αzi) (2.9)
where ψ0(t) is a non-negative baseline hazard function corresponding to the control group,
and zi is the treatment covariate for individual i, i = 1, . . . ,m. The treatment effect α can

















i exp{αzi}, k = 0, 1.
If {Yi(s), 0 < s} is independent of {Ni(s), 0 < s} given Zi and if (2.9) is correctly
specified, then (2.10) has expectation zero and the solution α̂ is consistent for the true
value, α. In the independence case, this true value is β if the treatment effect is common
(i.e. β = β1 = β2), or α = log(exp(β1) + exp(β2))/2 if the baseline hazard functions are
the same. More generally, however, α̂ is consistent for α∗, the solution to expected score





















where the expectation E is with respect to the true model for {N(t), Y (t), Z} (White,
1982; Struthers and Kalbfleish, 1986). By using the true model for {N(t), Y (t), Z} based
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on (2.5) and assuming independent censoring for the withdrawal time Wi with survival
distribution G(w|z) = G(w), these expectations can be obtained as follows:
E(S(1)(α, t)) = m [G(t)F(t|Z; Ω)] exp(α)P (Z = 1)




i=1 Ȳi(t)dNi(t)) = mG(t)
∑1
r=0F(t|Z = r; Ω)λ(t|Z = r)P (Z = r) ,
E(
∑m
i=1 ZiȲi(t)dNi(t)) = mG(t) [F(t|Z = 1; Ω)λ(t|Z = 1)P (Z = 1)] .
To illustrate the bias resulting from a composite endpoint analysis, consider a ran-
domized clinical trial in which subjects are to be followed over the interval (0, C†] where
C† = 1. Let Z = 1 for treated subjects and Z = 0 for control subjects and suppose
P (Z = 1) = 1 − P (Z = 0) = 0.5. We set β1 = β2 = β = log 0.80 to consider the case
compatible with the current recommendations on the use of composite endpoints. We set
λ1 and λ2 so that i) P (T1 < T2|Z = 0) = p1 equals a desired probability that the type
1 event occurs before the type 2 event among control subjects, and ii) P (C† < T ) = πA
satisfies the administrative censoring rate for the composite endpoint among all subjects,
where πA = 0.20. Finally, suppose subjects may withdraw from the study early, and
let W have an exponential distribution with rate ρ such that P (C < T ) = π, where
P (C < T ) = EZ [P (W < T < C
†|Z) + P (C† < T |Z)] and π is the overall censoring rate
set to π = 0.20, 0.40, 0.60 and 0.80.
Figure 2.2 shows the limiting percent relative bias (100(α∗ − β)/β) of the treatment
coefficient from a composite endpoint analysis when the data are generated by a Clayton
copula with mild (τ = 0.20) and moderate (τ = 0.40) association. The bias is plotted
against P (T1 < T2|Z = 0) = p1 and interestingly the bias is greatest when p1 = 0.50
but decreases as this probability approaches zero or one. In either of the extreme cases
(p1 = 0 or p1 = 1), the composite endpoint coincides with the occurrence of a single
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endpoint and a consistent estimate of the common treatment effect is obtained. Note that
the bias is negative in these plots, so α∗ < β, and hence the limiting value of the treatment
effect is more conservative than the true common value for each of the components. This
means that the estimated value would, on average, under-represent the magnitude of the
treatment effect on either component, a conclusion in line with the findings of Freemantle
et al. (2003) and DeMets and Califf (2002). Moreover, we note that the common event
rate and common treatment effect is precisely the setting where composite endpoints are
recommended for use (Freemantle et al., 2003; Montori et al., 2005; Chi, 2005; Neaton
et al., 2005). The plots also reveal the sensitivity of the limiting value to the degree of
random censoring; the higher the censoring rate, the smaller the asymptotic bias. This
highlights an important point that the limiting value of an estimator from a misspecified
failure time model is highly sensitive to the censoring distribution even under independent
censoring. By comparing the left and right panels in Figure 2.2 it is also apparent that the
asymptotic bias is dependent on the degree of association between T1 and T2; the greater
the association the greater the asymptotic bias. This makes sense since when the event
times are independent, consistent estimates should be obtained since assumptions A.1 (2.7)
and A.2 (2.8) are satisfied. Therefore, the treatment estimates from composite analysis
are lack of interpretability in the usual sense as the difference in relative risk between the
treatment group and the control group.
While of secondary interest, one can also show that ψ̂0(t), 0 < t < C
†, is consistent for
ψ∗0(t) =
∑1
r=0 G(t|Z = r)F(t|Z = r)λ(t|Z = r)P (Z = r)∑1
r=0 G(t|Z = r)F(t|Z = r) exp(α∗I(r = 1))P (Z = r)
which when P (Z = 1) = 0.5 and the censoring distribution is the same in the two groups
reduces to
ψ∗0(t) = [F(t|Z = 1)λ(t|Z = 1)+F(t|Z = 0)λ(t|Z = 0)]/[F(t|Z = 1) exp(α∗)+F(t|Z = 0)]
30
Figure 2.2: Asymptotic percent relative bias (100(α∗ − β)/β) of Cox regression coefficient
estimator for treatment effect from composite endpoint analysis when bivariate failure
times are generated by a Clayton copula; exponential margins, 20% administrative
censoring (πA = 0.20), 50:50 randomization, exp(β1) = exp(β2) = 0.80, and four different
degrees of additional random censoring (none, 20%, 40% and 60%).
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2.2.3 Simulation Studies Involving Composite Endpoints
Simulation Design:
Here we simulate data from (2.3) to examine the empirical performance of estimators for
finite samples. We assume that given Z, Tk has an exponential distribution with hazard
λk exp(βkZ), k = 1, 2, and model the association between T1 and T2 through a Clayton
copula. We let T = min(T1, T2) denote the time of the composite endpoint as before.
We suppose interest lies in following subjects over (0, 1]. As in the previous section, the
parameters λ1 and λ2 are determined to satisfy the constraints P (T1 < T2|Z = 0) = p1
where here p1 = 0.25, and P (C
† < T ) = πA where we set the administrative censoring
rate to πA = 0.20. Random loss to follow-up is also incorporated with an exponential
withdrawal time giving a net censoring rate of π = 0.20, 0.40, 0.60 and 0.80 subject to the
constraint πA ≤ π.
For each parameter configuration the sample size for the composite endpoint analysis
was derived to achieve a prespecified power under the assumption that the Cox model
holds. Therneau and Grambsch (2000) show the required number of events is D = 4(z1−γ1+
z1−γ2)
2/(α∗)2, where zq is the qth quantile of the standard Normal distribution, γ1 is the
type I error for a one-sided test, 1−γ2 is the power, and α∗ is the limiting value of treatment
effect estimate obtained from (2.9). We focus on two-sided tests at the 5% significance level
(γ1 = 0.05) and sample sizes to achieve 80% power (γ2 = 0.20). The required number of
subjects is calculated as m = D/P (T < C). In all simulation studies, we considered both
equal treatment effects (β1 = β2 = β = −.223) and unequal treatment effects (β1 = −.223
and β2 = 0). For each parameter configuration, we generated 2,000 replicates. We report
the mean of the α̂ estimates, the empirical standard error (ESE), the average model-based
standard error (ASE1) and the average robust standard error (ASE2). The empirical
coverage probability (ECP∗%) of nominal 95% confidence intervals for α∗ based on robust
standard errors and the empirical coverage probability of these intervals for β1 (ECP%)
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are also reported. The last column contains the empirical power (EP%) of a Wald test of
the null hypothesis of no treatment effect.
Composite Endpoints with Dependent Component:
Table 2.1 contains the simulation results with dependent component times given by τ =
0.40. The results for equal treatment effects are given in the top half of the table which we
comment on first. The fourth column contains α∗, the limiting value of the estimator from
the misspecified Cox model in (2.5). The fact that these values are all smaller in absolute
value than the true common effects reveals the conservative nature of this parameter, as
already discussed in relation to Figure 2.2; the dependence of the limiting value on the
degree of censoring is also apparent. This limiting value was used to derive the sample size
(m) in the third column. The average estimator from the fitted Cox models reported in the
fifth column closely approximates the limiting value. There is also close agreement between
the empirical, average model-based, and average robust standard errors. The empirical
coverage probabilities of the robust 95% confidence intervals are very close to the nominal
levels, and the empirical power is in good agreement with the nominal power of 80%. It
is worth noting that the empirical coverage probability is computed for the parameter α∗,
not the common β; for this latter parameter the coverage rates are considerably lower.
In the bottom half of Table 2.1, the results are reported for the case β1 6= β2, where α∗
is considerably smaller than β1. This smaller limiting values leads to considerably larger
sample sizes to achieve the desired power. Again, however, we see close agreement between
the average estimate and the limiting value, and very close agreement between the average
model-based and average robust standard errors. The empirical coverage probability (for
α∗) is also consistent with the nominal level, as is the empirical power.
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Table 2.1: Frequency properties of estimators of treatment effect based on a composite
endpoint with dependent components arising from a Clayton copula:
p1 = P (T1 < T2|z = 0) = 0.25, β1 = −.223 and τ = 0.4.
πA π m α
∗ AVE(α̂) ESE ASE1 ASE2 ECP
∗% ECP% EP%
Common Treatment Effect: β2 = −0.223
0.2 0.2 816 -0.195 -0.195 0.077 0.079 0.078 95.1 94.1 81.5
0.4 1071 -0.196 -0.197 0.078 0.079 0.079 95.4 94.3 80.0
0.6 1557 -0.199 -0.201 0.080 0.081 0.080 94.8 93.8 80.5
0.8 2908 -0.206 -0.207 0.085 0.083 0.083 94.4 94.5 79.4
0.4 0.4 1076 -0.196 -0.197 0.079 0.079 0.079 95.1 93.1 80.4
0.6 1557 -0.199 -0.201 0.081 0.080 0.080 94.7 93.6 79.8
0.8 2907 -0.206 -0.208 0.084 0.083 0.083 95.5 95.0 78.8
0.6 0.6 1522 -0.202 -0.201 0.082 0.081 0.081 94.9 94.3 79.0
0.8 2886 -0.207 -0.208 0.083 0.084 0.084 95.9 95.2 80.0
0.8 0.8 2779 -0.211 -0.208 0.087 0.085 0.085 94.8 94.1 78.5
Different Treatment Effects β2 = 0
0.2 0.2 21743 -0.038 -0.038 0.015 0.015 0.015 94.9 0.0 78.4
0.4 23103 -0.042 -0.042 0.017 0.017 0.017 94.9 0.0 79.4
0.6 26037 -0.049 -0.049 0.019 0.020 0.020 95.5 0.0 79.5
0.8 36581 -0.058 -0.058 0.024 0.023 0.023 94.2 0.0 79.3
0.4 0.4 19221 -0.046 -0.046 0.019 0.019 0.019 94.0 0.0 79.9
0.6 24084 -0.051 -0.051 0.020 0.020 0.020 95.1 0.0 80.1
0.8 36376 -0.058 -0.059 0.023 0.023 0.023 94.9 0.0 80.4
0.6 0.6 20656 -0.055 -0.055 0.022 0.022 0.022 94.9 0.0 81.8
0.8 34960 -0.059 -0.060 0.024 0.024 0.024 95.0 0.0 80.5
0.8 0.8 30990 -0.063 -0.064 0.025 0.025 0.025 95.4 0.0 81.4
πA = P (C
† < T ) is the administrative censoring rate, π = P (C† < T ) is the net censoring rate, ESE
is the empirical standard error, ASE1 is the average model based standard error, ASE2 is the average
robust standard error, ECP∗% is the empirical coverage probability for α∗ of a nominal 95% confidence
intervals using the robust standard error, ECP% is the empirical coverage probability for β1 of a nominal
95% confidence interval using the robust standard error, and EP% is the empirical power of a Wald test
of H0 : α = 0 based on the robust standard error.
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Composite Endpoints with Independent Components
Table 2.2 presents the simulation results with independent components (i.e. τ = 0). The
results in the top half of Table 2.2 reveal that the limiting value α∗ is the same as the
common value β = β1 = β2 as expected since assumption A.1 (2.7) is satisfied. Again
the average point estimate is is close agreement with this common value and the three
standard errors are in close agreement. When the treatment has an effect on T1 and
not T2, α
∗ is again considerably smaller than β1. Note, however, even though this is a
misspecified model, the limiting value does not depend on the censoring distribution. This
much smaller values leads to larger sample size requirements than in the top half of the
table. Because the first component T1 happens less frequently than the second component
T2, (i.e. P (T1 < T2|Z = 0) = 0.25), the limiting value from the misspecified Cox model
is heavily attenuated. However, neither administrative nor random censoring appear to
affect the limiting value of the estimator of treatment effect.
2.3 A Multivariate Semiparametric Analysis
2.3.1 Limiting Values for a Wei-Lin-Weissfeld Analysis
In this section, we investigate the utility of the marginal approach of Wei, Lin, and Weissfeld
(1989) for handling multivariate failure time data. This approach is based on formulating
ordinary Cox models for each component to obtain component-specific estimates of treat-
ment effect. Estimation proceeds under a working independence assumption like that often
adopted for generalized estimating equations. A robust estimate of the covariance matrix
is obtained and a global estimate of treatment effect is then obtained by taking a weighted
average of all component-specific estimates with weights chosen to minimize the variance
of the global estimator. A key distinction between global approach of Wei et al. (1989)
and the composite endpoint approach is that the former makes use of all observed events
35
Table 2.2: Frequency properties of estimators of treatment effect based on a composite
endpoint with independent components : p1 = P (T1 < T2|z = 0) = 0.25, β1 = −.223.
πA π m α
∗ AVE(α̂) ESE ASE1 ASE2 ECP
∗% ECP% EP%
Common Treatment Effect: β2 = −0.223
0.2 0.2 644 -0.223 -0.224 0.090 0.090 0.090 95.6 95.6 79.5
0.4 865 -0.223 -0.225 0.090 0.090 0.090 95.0 95.0 80.6
0.6 1310 -0.223 -0.227 0.090 0.090 0.090 95.3 95.3 80.7
0.8 2654 -0.223 -0.223 0.088 0.090 0.090 95.6 95.6 80.4
0.4 0.4 872 -0.223 -0.226 0.089 0.090 0.090 95.6 95.6 81.5
0.6 1315 -0.223 -0.226 0.090 0.090 0.090 95.8 95.8 80.3
0.8 2655 -0.223 -0.223 0.088 0.090 0.090 95.2 95.2 80.6
0.6 0.6 1323 -0.223 -0.223 0.091 0.090 0.090 95.1 95.1 79.9
0.8 2660 -0.223 -0.223 0.088 0.090 0.090 95.3 95.3 80.4
0.8 0.8 2670 -0.223 -0.221 0.091 0.090 0.090 94.8 94.8 78.5
Different Treatment Effects β2 = 0
0.2 0.2 11750 -0.051 -0.052 0.021 0.021 0.021 94.4 0.0 80.6
0.4 15666 -0.051 -0.052 0.021 0.021 0.021 94.9 0.0 81.0
0.6 23499 -0.051 -0.052 0.021 0.021 0.021 94.7 0.0 80.3
0.8 46998 -0.051 -0.052 0.020 0.021 0.021 95.6 0.0 81.2
0.4 0.4 15666 -0.051 -0.052 0.021 0.021 0.021 95.2 0.0 81.1
0.6 23499 -0.051 -0.052 0.021 0.021 0.021 95.3 0.0 80.1
0.8 46998 -0.051 -0.052 0.020 0.021 0.021 95.3 0.0 81.3
0.6 0.6 23500 -0.051 -0.052 0.021 0.021 0.021 94.1 0.0 81.5
0.8 46998 -0.051 -0.052 0.020 0.021 0.021 95.6 0.0 81.4
0.8 0.8 46999 -0.051 -0.051 0.021 0.021 0.021 94.7 0.0 80.6
πA = P (C
† < T ) is the administrative censoring rate, π = P (C† < T ) is the net censoring rate, ESE
is the empirical standard error, ASE1 is the average model based standard error, ASE2 is the average
robust standard error, ECP∗% is the empirical coverage probability for α∗ of a nominal 95% confidence
interval using the robust standard error, ECP% is the empirical coverage probability for β1 of a nominal
95% confidence interval using the robust standard error, and EP% is the empirical power of a Wald test
of H0 : α = 0 based on the robust standard error.
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whereas the composite endpoint uses only the first event. The robust variance estimate is
used to account for possible correlation in the data.
We proceed in the derivations in the case where the composite endpoint is comprised of
K components but subsequently will focus on the case K = 2. We let dNik(s) = I(Tik =
s), and let {Nik(s), 0 < s} denote the counting process for type k events and {Ni(s) =
(Ni1(s), Ni2(s), 0 < s} denote the bivariate counting process for subject i, i = 1, . . . ,m.
Let Yik(s) = I(s ≤ Tik), Y †i (s) = I(s ≤ Ci) and Ȳik(s) = Y
†
i (s)Yik(s), k = 1, . . . , K,
i = 1, . . . ,m. A Cox model is assumed for type k events meaning
λk(t|zi) = λk0(t) exp(βkzi) ,
where λk0(t) is the baseline hazard function for type k events and βk is the treatment effect























i exp{βkZi}, r = 0, 1.
Under the copula model of Section 2.2.1, the proportional hazards assumption holds for
each component and the solution to the score equation (2.12), β̂k, is a consistent estimate
of true treatment effect βk. If we let β = (β1, ..., βK)
′ and its estimate β̂ = (β̂1, ..., β̂K)
T ,
Wei et al. (1989) show that
√
m(β̂− β) converges in distribution to a multivariate Normal
distribution with zero-mean vector and variance-covariance matrix Σ(β) and provided a
consistent sandwich-type estimate for Σ(β).
The global estimate of treatment effect proposed by Wei et al. (1989) is simply a linear
combination of all component-specific treatment effect estimates β̂1, . . . , β̂K and can be
obtained as ̂̄β = c(β̂)′β̂ , (2.13)
where the weight c(β̂) = Σ̂(β̂)−1Ĵ[Ĵ′Σ̂(β̂)−1J]−1 is chosen to estimate the weight matrix
to minimize the variance in the class of all linear estimators; Σ̂(β̂) is the estimate for the
variance-covariance matrix of β̂ and J = (1, ..., 1)′.
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Table 2.3: Frequency properties of estimator of treatment effect based on global analysis
using the Wei-Lin-Weissfeld approach: Clayton copula with τ = 0.4, β1 = −.223.
πA π m β̄ AVE(α̂) ESE ASE1 ASE2 ECP
∗% ECP% EP%
Common Treatment Effect: β2 = −0.223
0.2 0.2 621 -0.223 -0.223 0.084 0.072 0.086 95.9 95.9 83.6
0.4 828 -0.223 -0.223 0.086 0.074 0.087 95.1 95.1 82.0
0.6 1242 -0.223 -0.221 0.088 0.077 0.088 95.0 95.0 80.8
0.8 2484 -0.223 -0.223 0.089 0.083 0.090 95.6 95.6 80.3
0.4 0.4 828 -0.223 -0.223 0.087 0.076 0.087 95.4 95.4 82.7
0.6 1242 -0.223 -0.221 0.089 0.078 0.088 95.0 95.0 79.9
0.8 2484 -0.223 -0.223 0.089 0.083 0.090 95.6 95.6 80.6
0.6 0.6 1242 -0.223 -0.223 0.090 0.081 0.089 95.1 95.1 79.7
0.8 2484 -0.223 -0.222 0.089 0.083 0.090 95.2 95.2 80.5
0.8 0.8 2484 -0.223 -0.225 0.088 0.086 0.090 95.2 95.2 80.5
Different Treatment Effects β2 = 0
0.2 0.2 7090 -0.066 -0.067 0.025 0.021 0.025 95.9 0.0 84.2
0.4 9664 -0.065 -0.066 0.025 0.022 0.025 94.5 0.0 83.3
0.6 14623 -0.065 -0.066 0.026 0.023 0.026 94.8 0.0 82.8
0.8 28219 -0.066 -0.066 0.026 0.024 0.027 95.3 0.0 81.7
0.4 0.4 10203 -0.064 -0.065 0.025 0.022 0.025 95.1 0.0 83.6
0.6 14897 -0.064 -0.066 0.025 0.023 0.025 94.6 0.0 83.2
0.8 28316 -0.066 -0.066 0.026 0.024 0.027 95.2 0.0 80.6
0.6 0.6 14733 -0.065 -0.066 0.026 0.024 0.026 94.1 0.0 83.4
0.8 28202 -0.066 -0.067 0.026 0.025 0.027 95.2 0.0 81.7
0.8 0.8 27355 -0.067 -0.069 0.026 0.026 0.027 95.4 0.0 82.2
πA = P (C
† < T ) is the administrative censoring rate, π = P (C† < T ) is the net censoring rate, ESE
is the empirical standard error, ASE1 is the average model based standard error, ASE2 is the average
robust standard error, ECP∗% is the empirical coverage probability for β̄ of a nominal 95% confidence
interval using the robust standard error, ECP% is the empirical coverage probability for β1 of a nominal
95% confidence interval using the robust standard error, EP% is the empirical power of a Wald test of
H0 : β = 0 based on the robust standard error.
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In order to compare the performances of the global approach and the composite end-
points analysis, we obtain the limiting value of ̂̄β as
β̄ = c(β)′β , (2.14)
where c(β) = Σ−1(β)J[J′Σ−1(β)J]−1. We therefore require the limiting value of the robust
variance Σ(β) to obtain the limiting value β̄. The detailed derivations are deferred to the
Appendix.
2.3.2 Comparison of the Global Approach and Composite End-
points
Table 2.3 reports the results from a global analysis of treatment effect based on the marginal
analysis proposed by Wei et al. (1989). In this table the sample sizes were computed
based on the formula for the composite endpoint analysis using the limiting value of the
regression coefficient. As one would expect from (2.12), when the treatment effects are
equal then the marginal analysis yields consistent estimators for this common effect and
the mean estimate across all simulated trials is very close to the limiting value. Moreover,
the empirical standard error and the average robust standard error were in very close
agreement; the average model-based standard error is conservative since it is based on
the working independence assumption being correct. The empirical coverage probabilities
(based on the robust standard errors) were compatible with the nominal 95% level for β̄
when β1 = β2. When β1 6= β2 the empirical coverage for β1 was zero, a reflection of the
difference between β̄ and β1. When β2 = 0, the limiting value β̄ was quite small and hence
the sample sizes of the trial were much larger. Since the sample size was computed based
on the composite endpoint analysis with β̄, it is not surprising that there is a slight gain in
empirical power from the global analysis since each individual may contribute more than
one event.
When β1 6= β2, the composite endpoint and global analyses yield estimators which do
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not coincide with β1, β2, or each other. We next compare the two limiting value: one is α
∗
from the composite endpoint analysis and the other one is β̄ from the global analysis. We
consider the case in which two failure times are generated by a Clayton copula with ex-
ponential margins and a single treatment covariate modeled through proportional hazards
with β1 = log(0.80) and β2 = 0. We consider mild and moderate association between the
failure times with τ = 0.20 and τ = 0.40 respectively. Administrative censoring was set
to 40% and additional random censoring from an exponential withdrawal time gave cases
with 60% and 80% as well. The limiting value of the composite endpoint and global anal-
yses were plotted against P (T1 < T2|Z = 0) = p1 in Figure 2.3. It is apparent that when
p1 approaches zero, the limiting value for both methods approaches 0. For the composite
endpoint this makes sense since the first event is most likely to be a type 2 event for which
there is no treatment benefit. As p1 approaches 1, the limiting value for the composite
endpoint analysis approaches β1 for analogous reasons. The limiting value from the global
analyses track these limiting values quite well, but tend to correspond to larger estimates
of treatment effect since the limiting value is larger in absolute value. Thus even when the
two components have equal frequencies and the proportional hazards assumption holds for
each component, the global analysis, in the limit, will yield an estimate of treatment effect
which is greater than that of the composite endpoint analysis. These relationships hold
across both levels of association and over different degrees of censoring.
2.4 Application To An Asthma Management Study
We now apply both the composite endpoints analysis and the global approach to an asthma
management study (Jayaram et al., 2006). This is a two-phase, multicenter, randomized,
parallel group-effectiveness study for two treatment strategies in asthma management over
a 2-yr period. The first one is a clinical strategy (CS) , in which the treatment was based
on symptoms and spirometry. The second one is a sputum strategy (SS), where the sputum
40









































































































































































































Figure 2.3: Plot of limiting values of regression estimator of treatment effect based on a
composite endpoint analysis and a global Wei-Lin-Weissfeld (1989) analysis with
bivariate data generated via a Clayton copula; β1 = log(0.8) and β2 = 0; administrative
censoring only.
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cell counts were used to guide contricosteriod therapy to keep eosinophils less than 2%. In
phase I a total of 107 patients were identified through the minimum treatment to maintain
control. The aim of this asthma study was to investigate whether SS is more effective than
CS on reducing the number and severity of exacerbations in phase II.
Table 2.4: Results of the data from asthma management study.
RR 95% CI p-value p*
Moderate-to-Severe 0.53 (0.285, 0.977) 0.042 0.22
Very Mild-to-Mild 2.14 (0.624, 7.310) 0.227 0.11
Composite Endpoint 0.665 (0.388, 1.138) 0.137 0.063
Global (WLW) 0.702 (0.405, 1.219) 0.209
In our analysis we focus on two types of exacerbations: very mild-to-mild exacerbation
(minimum daily maintenance fluticasone equivalent dose < 250µg) and moderate-to-severe
exacerbation (minimum daily maintenance fluticasone equivalent dose ≥ 250µg). The
composite endpoint is defined as the time to the first of the two type of exacerbations.
The Figure 2.4 display the probability plots of the two types of exacerbations and the
composite endpoint. Clearly, the moderate-to-severe exacerbation happens much more
frequent than the very mild-to-mild type. The plot of composite endpoint resembles that
of the moderate-to-severer type, that is, majority of the composite endpoint is moderate-
to-severe type. We also estimate the association between the two types of exacerbations by
estimating Kendall’s τ nonparametrically using the function cenken()in the package NADA
in R. The data were modified to change the right censoring into left truncation to fit the
requirement of the function cenken(). For each individual, new censoring times or event
times were created by subtracting the corresponding censoring times or event times of the
two types of exacerbations from the total follow-up time. The censoring status was kept
the same. In this way, a right-censored observation in the original data was changed into a
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Figure 2.4: Estimated cumulative probability of server and mild of exacerbations and the
composite endpoint.
left-truncated observation in the modified data. Since the follow-up duration of this study
was fixed at two years, this modification will preserve the association between two types
of exacerbations. The estimated Kendall’s τ is approximately 0 with a p-value close to 1
for a test of H0 : τ = 0. This indicates that there is no statistically significant association
between the two types of exacerbations and the composite endpoint analysis is applied to
independent components.
Table 2.4 presents the analysis results. The SS has significant effect on reducing the
number of moderate-to-severe type of asthma but has no significant effect on the very
mild-to-mild type. Neither the composite endpoint analysis nor the the global approach
is not statistically significant. The last column of Table 2.4 gives the p-values for testing
the proportional hazards assumption, obtained by using the cox.zph() in the survival
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package in R. This assumption holds for each component but is only not rejected for the
composite endpoint. We have demonstrated that, in principle, the proportional hazards
assumption generally does not hold for the composite endpoint. In the asthma study
the proportional hazards assumption was not rejected, because there were only about one
hundred of patients and we may not have enough power to reject the null hypothesis of
proportional hazards.
2.5 Discussion
Composite endpoints are widely adopted in clinical trials and fitting a Cox proportional
hazards model is the standard approach to estimating the treatment effect on the basis of
these endpoints. We have demonstrated that even when the treatment effects are the same
for component endpoints under marginal Cox models, the Cox model for the composite
endpoint is misspecified and yields a conservative point estimate of treatment effect. Using
asymptomatic theory, we investigated the limiting behaviour of the treatment effect esti-
mator from based on this misspecified Cox model and found that there are many factors
that jointly affect the estimator of treatment effect. These factors include the strength of
the association between the individual component events, stochastic ordering of the indi-
vidual components, and the degree and nature of the censoring process. While we have
not explored this here, it is clear from the material in Section 2.2.1 that the type of copula
function would also have an important effect.
The above concerns apply when the treatment effect is common across the components,
but more generally variation in the treatment effect across the individual components can
make it even more difficult to assess estimators of treatment effect. Another reason for
the use composite endpoints is the measure of “overall effect” of a treatment (Cannon,
1997). When the treatment has some adverse effect on one particular component and
the composite endpoint supposes to capture this. However, if this component has low
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frequency and masked by the component with positive treatment effect, the composite
endpoint analysis may fail to capture the adverse effect. The global approach, however,
can detect the adverse effect in the componentwise analysis and then account for this in
the combined estimates through its weight (a function of its frequency).
One rationale put forward for adopting composite endpoints is to fit models for the
event-free survival probability. For example, Sheehe (2010) proposed that the event-free
survival curve can be computed based on Cox model estimates of hazard ratios from the
composite endpoint containing mortality as a component. As we demonstrated in this
study, effect estimation from Cox model analysis of composite endpoints can be biased
or attenuated, therefore, using the treatment estimates from the composite endpoint to
estimate the event-free survival probability may not accurate.
As a remedy for problems caused by unequal treatment effect and unequal frequencies
among components, two guidelines had been proposed as in medical literature: individual
component in composite endpoint should be of equal frequency and the treatment effect
should be equal across the all components. Our analytical and empirical investigation shows
that these are not be valid recommendations in the sense that when these conditions are
satisfied, the association between the two events can lead to substantial bias in resulting
estimators. On the other hand, we support the following recommendations in the medical
literature that i) data from all components should be followed until the end of the trial and
ii) individual components should be analyzed separately and results reported separately.
This alternative design and analysis allow our proposed global approach to combine the
effect estimates from individual components to form an average estimate of the treatment.
Through both analytical comparisons and simulation studies we demonstrated that this
global approach, in general, outperforms the composite endpoint analysis in terms of the
properties of the resulting estimators and sample size requirements.
We have assumed independent censoring in this paper. We have formulated a model
with proportional hazards for each component through the use of a copula function. We
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have done this to, in some sense, reflect an idealized situation in line with the recommen-
dations above. Alternative models could naturally be specified for correlated failure time
data. One might, for example, consider the risk of one type of event to change with the
occurrence of another type of event and manifest this effect through a multiplicative effect
on the respective hazard through a time-dependent covariate. This could arise because of
a biological mechanism in which the medical risk actually increases, or if treating physi-
cians alter the therapy being given. This formulation, while natural for characterizing the
response process, is not compatible with proportional hazards for the marginal models.
One might also consider frailty models for addressing the association between event times,
but again, the marginal models will not have a proportional hazards form.
Another way in which patients may be treated differently following the occurrence of a
clinically important event, is to be withdrawn from a study. The occurrence of one event
may increase the risk an investigator may withdraw the patient from the study and result in
response-dependent censoring. If the events are independent conditional on the treatment
covariate, this will not pose a problem, but otherwise will lead to biased estimates of the
baseline hazard functions and treatment effects. Use of inverse probability of censoring
weights will help reduce this bias and this is currently under investigation.
Finally, we have focussed on the frequency properties of estimators under a Cox regres-
sion models. There is increasing interest in using alternative regression models for survival
data including accelerated failure time models and additive models. Exploration of the
behaviour of estimators from such models would also be of interest.
2.6 Future Work
We intend to develop methods for sample size calculation based on the Wei et al. (1989)
analysis where the asymptotic variance is obtained under the assumption that the joint
distribution is governed by a Copula; this model is chosen so it is compatible with the
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assumptions of the marginal semiparametric method of Wei et al. (1989), namely the
treatment effect acts multiplicatively as the individual endpoints.
In this section we briefly outline the strategy for sample calculation for the approach
of Wei et al. (1989) with copula models. Let ̂̄β be the combined estimate from the WLW
approach. The null hypothesis is
H0 :
̂̄β = 0
and the alternative hypothesis is
HA :
̂̄β = β̄
From Wei et al. (1989), we know that
n1/2(̂̄β − β̄) ∼ N(0, (J′DJ)−1)
where β̄ is the limiting value of the combined estimate ̂̄β and D is the limiting value of
D̂(β̂), the variance of β̂. Using the Clayton copula model (2.5) with prespecified parameters
and a prespecified censoring distribution, we can obtain D using the method outlined in
the Appendix. For a one-sided test with significance level γ1 and a given power 1 − γ2,
where γ2 the type 2 error rate, for the hypothesis testing problem above, we use a Wald




Under H0, it has the standard normal distribution, and let zγ1 be the 100γ1%th quantile
of standard normal distribution.
Then, under HA, we have
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hence we have Φ(zγ1 − β̄/
√
n−1V ) = 1− γ2 and the required sample size is
n =




2.7.1 Derivation of the Limiting Value β̄
Under the copula model, the proportional hazards assumption holds for each component,
and the limiting value for β̂k is βk. Let S
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by the Theorem 4.2 of Andersen and Gill (1982). In the present setting, the true model is
known and the required expectations can be obtained in closed form and the integral can




















and wi(β) = (wi1(β1), ..., wiK(βK))
′ (Wei, Lin, Weissfeld, 1989). Then if we define B(β) =
E(wi(β)wi(β)
′), the asymptotic robust covariance matrix Σ(β) takes the formA(β)−1B(β)A(β)−1
(Wei et al., 1989). This can be used to obtain the limiting value through (10).
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The entries of B(β) are obtained as follows. The (j, j) element of B(β) is



























where 〈·, ·〉 is the predictable covariation process and the last equality holds due to Fubini’s
theorem (Fleming and Harrington, 1991). The (j, k) element of B(β) is then






















Using the covariance function for correlated martingales of Prentice and Cai (1992), the
term 〈dMj(tj), dMk(tk)〉 can be obtained. In the case of bivariate data, 〈dM1(t1), dM2(t2)〉
is obtained simply as
〈dM1(t1), dM2(t2)〉 = F(dt1, dt2|zi; Ω)dt1dt2 + F(t1, dt2|Zi; Ω)Λ1(dt1|zi; Ω)dt1dt2
+F(dt1, t2|zi; Ω)Λ2(dt2|zi; Ω)dt1dt2
+F(dt1, dt2|zi; Ω)Λ1(dt1)Λ2(dt2|zi; Ω)dt1dt2,
where Λk(dtk|zi; Ω) = dΛk(tk|zi; Ω)/dtk; F(dt1, dt2|zi; Ω) = ∂2F(t1, t2|zi; Ω)/∂t1∂t2,
F(dt1, t2|zi; Ω) = ∂F(t1, t2|zi; Ω).∂t1, F(t1, dt2|zi; Ω) = ∂F(t1, t2|Zi; Ω)/∂t2. More specifi-
cally, if the joint survivor function F(t1, t2|zi; Ω) is specified by the Clayton copula with
margins of two exponential distributions, then 〈dMj(tj), dMk(tk)〉 can be obtained in closed
form and E(wij(βj)wik(βk)) can be obtained through numerical integration. Thus, we ob-
tain the limiting value of robust variance, then the limiting weights can be calculated using
c(β) = Σ−1(β)/J′Σ−1J and the limiting value β̄ using equation (2.14).
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Chapter 3
Dependent Censoring in Marginal
Analysis of Multivariate Failure Time
Data
3.1 Introduction
Many chronic disease processes make individuals at risk for multiple type of events and
it is often of interest to examine the effect of treatment on the risk of occurrence for
each type of event (Hougaard, 2000; Dabrowska, 2006). In settings involving life history
profiles, multiple events can occur during a particular period of observation and composite
endpoints are also routinely used as a basis for treatment assessment (Freemantle et al.,
2003). In time to event data, a composite endpoint simply uses the time of the first event
as the response, regardless of the type, and is appealing since it permits the use of standard
methods for survival analysis (Lawless, 2003; Kalbfleisch and Prentice, 2002).
While use of a composite endpoint simplifies the data, it does not lead to a treat-
ment comparison based on a full characterization of the disease process. For this reason,
in clinical trials investigators have increasingly turned to use of multiple endpoints and
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regulatory agencies are increasingly requiring demonstration of efficacy new interventions
based on such analyses (Freemantle and Calvert, 2007a; Buzney and Kimball, 2008; Wei
and Glidden, 1997; Fleming and Lin, 2000).
There are three common frameworks for the analysis of multivariate failure time data in-
cluding frailty-based models (Therneau and Grambsch, 2000), copula models (Liang et al.,
1995; Nelsen, 2006), and marginal methods (Wei et al., 1989). While frailty models and
copula models yield multivariate distributions, they require distributional assumptions re-
garding the frailty distribution and the copula function respectively. These fully specified
models can be useful if interest lies in estimating the degree of association between two
or more event times or prediction. When assessing treatment effects in clinical trials it is
generally desirable to make minimal assumptions and maintain robustness. The marginal
approach of Wei et al. (1989) has the appeal of being based on specification of one Cox
regression model for each type of event but no specific of a dependence structure among
the distinct failure times. Simultaneous inference regarding the estimates of the marginal
regression coefficients is carried out through use of a robust sandwich type variance es-
timator. This method is easily implemented in most major statistical software packages
such as R/S-PLUS and SAS (Therneau and Grambsch, 2000) and is widely used in clinical
trials (Lin, 1994).
The marginal approach of Wei et al. (1989) is based on a working independence as-
sumption and the robust covariance matrix and hence has similarities with the approach
of generalized estimating equation of Liang and Zeger (1986) for dealing with clustered
categorical data. A number of methodological advances have been made in the field of
multivariate failure time data analysis which are based on a similar framework (Lee et al.,
1992; Liang et al., 1993; Cai and Prentice, 1995, 1997; Spiekerman and Lin, 1998; Clegg
et al., 1999, 2000; Greene and Cai, 2004; Cai and Schaubel, 2004; Yin and Cai, 2004, 2005;
Cai et al., 2005, 2007; Kang and Cai, 2009). Since the marginal approach of Wei et al.
(1989) is based on a partially specified model, however, it is only valid if censoring is com-
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pletely independent of the failure time process. In studies of life history processes, when
individuals are to be followed after the occurrence of events, it is common for censoring
to be associated with occurrence of one or more particular types of events, yielding event-
dependent censoring. For example, if the occurrence of the first event alerts a physician
to the fact that the current treatment is “not working” for a patient, it may increase the
risk that they will be withdrawn from the study. In general, when marginal regression
models are applied to multivariate failure times under such a dependent censoring scheme,
biased (martingale) estimating equations are specified and the resulting estimators are
inconsistent (?). We advocate the use of inverse probability of censoring estimating equa-
tions for marginal analysis of multivariate failure times data when there is concern about
event-dependent censoring.
3.2 Notation and Model Specification
3.2.1 Model Formulation for Multivariate Failure Times
Let Tk denote the time of the type k event and {Nk(s), 0 < s} denote the corresponding
right-continuous counting process, where Nk(t) = I(Tk ≤ t) indicates that the type k
event has occurred at or before time t, dNk(t) = 1 if a type k event occurs at time t,
and dNk(t) = 0 otherwise. We further let N(t) = (N1(t), . . . , NK(t))
′ and remark that the
multivariate counting process {N(s), 0 < s} is often useful to specify when interest lies
in jointly modeling the occurrence of all event types. Suppose Z(t) is a vector of fixed,
exogenous or endogenous covariates and let {Z(s), 0 < s} denote the covariate process.
The full history at t contains information on the number and times of events over [0, t)
and covariate data over [0, t] and is denoted H(t) = {N(s), 0 ≤ s < t, Z(s), 0 ≤ s ≤ t}.
The intensity function for type k events is
λk(t|H(t)) = lim
∆t→0




where ∆Nk(t) = Nk(t+∆t
−)−Nk(t−) is the number of the events occurring over the interval
[t, t+ ∆t). The association between processes is accommodated through the inclusion of a
dependence on the history for process ` in the intensity for type k events. For continuous
time processes where at most one event can occur at any time, these intensity functions
fully define the multivariate counting processes (Andersen et al., 1993).
While this formulation completely specifies a multivariate model, in the context of clin-
ical trials it is undesirable to assess treatment effects conditional on endogenous variables
(Kalbfleisch and Prentice, 2002) and hence intensity functions do not offer an appealing
framework for analyses. Instead treatment effects are more naturally expressed in terms
of marginal proportional hazards regression models of the form
λk(t|Z) = λ0k(t) exp(βkZ) (3.1)
where λ0k(t) is an unspecified positive function, βk is a regression parameter and Z is a
fixed covariate which equals 1 for individuals receiving the experimental treatment and
zero for those receiving a control therapy. The marginal hazard ratio reflecting the effect
of treatment on type k events is then simply exp(βk). The cumulative baseline hazard func-
tion is Λ0k(t) =
∫ t
0
λ0k(u)du and the marginal survivor function is Fk(t|Z; θk) = P (Tk ≥
t|Z; θk) = exp(−Λ0k(t)eβkZ), where θk contains the regression coefficient βk and the pa-
rameters indexing λ0k(·). When marginal models of this type are specified it is necessary
to address the association in the failure times differently than is done for intensity-based
analyses. This is conveniently achieved using copula functions (Nelsen, 2006).
A copula function Cφ(u1, . . . , uK) in K dimensions defines a multivariate distribution on
the unit hypercube [0, 1]K with uniform margins. Parametric copula functions are indexed
by a parameter denoted by φ, which characterizes the association between the components
of the marginal quantities. Such functions offer a convenient way of constructing multivari-
ate distributions with marginal distributions of a specified form. Specifically, the marginal
probability integral transformation of each random variable can be applied to create a K
dimensional vector of uniform random variables. These in turn are then viewed as the com-
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ponents of a multivariate uniform random variable with their joint distribution governed
by a given copula. Thus the joint survival function F12(t1, t2|z) = P (T1 ≥ t1, T2 ≥ t2|z)
can be specified by linking the two marginal survival functions via a copula function
F12(t1, t2|z; Ω) = Cφ(F1(t1|z; θ1),F2(t2|z; θ2)) ,
where Ω = (θ′, φ)′ with θ = (θ′1, θ
′
2)
′. The Clayton copula is widely used in survival analysis
and yields a joint survival distribution of the form
Cφ(F1(t1|z; θ1),F2(t2|z; θ2)) =
(
[F1(t1|z; θ1)]−φ + [F2(t2|z; θ2)]−φ − 1
)−1/φ
.
The degree of association between two failure times is often expressed in terms of Kendall’s
τ which is given by τ = φ/(φ + 2) (0 ≤ τ ≤ 1) for the Clayton copula where τ = 0 and
τ = 1 correspond to the cases of independence and perfect association respectively.
3.2.2 A Model for Event-Dependent Censoring
When multiple clinical events arise investigators often withdraw patients from trials if there
is a perception that the randomized treatment is no longer appropriate. If subjects are
censored at the time of study withdrawal, this creates a type of event-dependent censoring
which leads to inconsistent parameter estimates under partially specified models. Consider
a setting in which the intention is to follow individuals over the interval [0, C†) where C† is
a time of administrative censoring. Let C denote a random time of withdrawal where 0 <
C ≤ C†. Let NC(t) = I(C ≤ t) and {NC(s), 0 < s} be the counting process for the random
censoring time where dNC(t) = 1 if random withdrawal occurs at time t and dNC(t) = 0
otherwise. Let Y †(s) = I(s ≤ C†), Y (s) = I(s ≤ C), Ȳ (s) = Y (s)Y †(s) and Ȳk(s) =
Ȳ (s)I(s ≤ Tk) indicate whether an individual is under observation and at risk of a type
k event. Let dN̄k(t) = Ȳk(t)dNk(t), N̄k(t) =
∫ t
0
dN̄k(s), and N̄(t) = (N̄1(t), . . . , N̄K(t))
′.
We observe {(N̄(s), NC(s)), 0 < s ≤ C†, Z} and let H̄(t) = {(N̄(s), NC(s)), 0 < s < t, Z}
denote the observed history for the event and censoring processes.
54
The intensity for the random censoring time C is
λc(t|H̄(t)) = lim
∆t→0
P (∆NC(t) = 1|H̄(t))
∆t
, (3.2)
which accommodates dependence between the censoring, event times, and possibly the
treatment assignment. It is the dependence on the event times that is particularly problem-
atic when the analysis of the failure times is based on a working independence assumption,
often adopted for multivariate failure time data (Wei et al., 1989).
The dependence on the event history can take many forms, but in what follows we
consider a particular model with the censoring intensity
λc(t|H̄(t)) = λc0(t) exp(α1N1(t) + α2N2(t)) , (3.3)
where λc0(t) is a baseline intensity for censoring and (α1, α2)
′ are regression coefficients
which reflect how the risk of withdrawal changes upon the occurrence of type 1 and type
2 events; we write dΛc0(t) = λ
c
0(t)dt. Thus exp(αk) is the multiplicative factor by which
the intensity of censoring increases upon the occurrence of a type k event, k = 1, 2, and if
α1 = α2 = 0, min(C,C
†) is an independent right-censoring time.
3.3 Asymptotic Biases of Marginal Estimators
In this section, we investigate the asymptotic bias caused by event-dependent censoring
when marginal estimating equations are specified based on a working independence assump-
tion, as is done for the multivariate approach of Wei et al. (1989). We first present the
general framework and then study the one-sample estimates in detail. The data for a sample
of n independent individuals are denoted by {(N̄i(s), NCi (s)), 0 < s ≤ C†, Zi, i = 1, . . . , n}
where we introduce the subscript i to index individuals. We assume that the marginal
distribution of Tik|zi is exponential with λk(t|zi) = λik(t) = λk exp(βkzi) and the joint
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Ȳik(u) (dNik(u)− dΛik(u))zi) (3.5)
where dΛik(t) = exp(βkzi)λ0k(t)dt, k = 1, 2. The profile estimate of the cumulative baseline
















Ȳik(u)(dNik(u)− dΛ̃0k(u; βk) exp(βkzi))zi = 0 (3.7)
and upon substitution of β̂k into (3.6) the Breslow estimate Λ̂0k(t) = Λ̃0k(t; β̂k) is obtained.
With completely independent censoring the above estimating equations yield consistent
estimators of the cumulative baseline hazard function Λ0k(t) =
∫ t
0
λ0k(u)du, as well as the
regression coefficient βk, k = 1, 2. If censoring is governed by an intensity featuring a
dependence on the event history, (3.4) and (3.5) may yield inconsistent estimators. The
limiting value of the estimator of the cumulative baseline hazard function under a general
























] E [Ȳik(t)dNik(t)] . (3.9)
The expectation E(·) in (3.8) and (3.9) is taken with respect to the true process defined
here in terms of the marginal distributions, the Clayton copula, and the event-dependent
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censoring intensity (3.3). Details on these calculations are given in the Appendix at the
end of this Chapter.
To illustrate the bias of the naive marginal approach in estimation of the cumulative
hazard function, we consider a separate analysis of two treatment groups; in this case we
restrict attention to (3.4) with zi = 1 for the treatment group and zi = 0 for the control
group. The Nelsen-Aalen estimator of Λ0k(t) is




i=1 Ȳik(t)I(Zi = z)dNik(t)∑n
i=1 Ȳik(t)I(Zi = z)
. (3.10)
The bias of this estimator is investigated by calculating the limiting value of 3.10 with
respect to the true process. The two types of events have an equal risk with λk = 2,
k = 1, 2 and C† chosen to give 10% administrative censoring. A Clayton copula model was
used to induce an association between the failure times with τ = 0.2 and τ = 0.6. The





was chosen to give about 35% random censoring on the first type of event by the end of
study. Figure 3.1 displays the true cumulative hazard function and naive estimates based
on the Nelson-Aalen estimator when τ = 0.2 and τ = 0.6; the left panel contains the
results for type 1 events and the right panel for type 2 events. The plots demonstrate that
the naive method yields a conservative estimate of the cumulative hazard function with
the magnitude of this bias increasing with time. The stronger the association between the
failure times, the greater the empirical bias. It is interesting to note that the bias is greater
for the estimated cumulative hazard for type 1 events since the strength of the dependence
between type 2 event times and censoring is greatest.
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Figure 3.1: Plots of the true cumulative hazard functions for type 1 (left panel) and type
2 (right panel) events along with limiting values of the corresponding naive (unweighted)
Nelson-Aalen estimates when τ = 0.2 and τ = 0.6; bivariate failure time model defined by
a Clayton copula with exponential margins (λ1 = λ2 = 2); C
† chosen to give 10%
administrative censoring; dependent censoring intensity with α1 = log 1.3 and
α2 = log 3.5 with λ
c
0 chosen to given about 35% random censoring rate.
58
3.4 IPCW Weighted Marginal Regression
3.4.1 IPCW Weighted Estimating Equations
The estimating equations (3.4) and (3.5) can be modified to yield consistent estimators
by introducing inverse probability of censoring weights (Robins, 1993). If, as in (3.3),
the censoring intensity for individual i at time t depends on the history H̄i(t), then let







. Furthermore let G(t) be survival function of
the random right censoring time under the scenario of independent random censoring, in
which case the censoring intensity is a hazard function with λc(t)dt = dΛc(t); note we drop
the subscript 0 here since it is no longer a baseline censoring intensity. Then again by
product integration we obtain G(t) =
∏
u<t [1− dΛc(u)] .














(dNik(u)− dΛik(u)) zi , (3.12)
respectively. The weights are introduced to ensure that the resulting marginal estimating
equations are unbiased and hence that consistent estimators are obtained. As an example,
we demonstrate E(Uk1(t)) = 0. Since G(t) does not depend on the process history, it




[dNik(t)− dΛik(t)]) = 0.








Furthermore, by taking expectation of the right hand size in the above expression with




EHi(t)(Yi(t)dΛik(t))− EHi(t)(Yi(t)dΛik(t)) = 0.
Hence, we have demonstrated that this is an unbiased estimating equation for the estima-
tion of Λik(t). By similar arguments it can be shown that the expectation of (3.12) is also
zero.
From the derivations above it is clear that G(t) is not necessary to guarantee unbiased-
ness of the estimating equations. In fact it will have no role in estimation of the baseline
hazard function since it cancels in the numerator and denominator of Breslow’s estimator
given in (3.11). Robins (1993) showed, however, that inclusion of G(t) yields estimators of
βk which are more efficient (3.12) than those obtained when G(t) = 1.
In practise, of course, to use (3.11) and (3.12) the functions G(t) and Gi(t) must be
consistently estimated. Let Λc(t) =
∫ t
0
dΛc(u)du where dΛc(u) = λc(u)du is the crude
censoring hazard under the working independence assumption between the censoring and

















the usual Kaplan-Meier estimate of the survival function for the censoring distribution.
Correct specification of the model for Gi(t) is more crucial since it is what renders
the inverse weighted estimating functions unbiased. If one believes the censoring intensity
function (3.3) is correct, one can adopt it in the following. Alternatively, we prefer to relax
the proportionality assumptions in (3.3) and consider a more robust stratified model for
the censoring intensity with dΛc(t|Hi(t)) = dΛc(t|Ni1(t) = l, Ni2(t) = m) = dΛclm(t), where
l,m = 0, 1. The corresponding nonparametric estimate is then
dΛ̂c(t|H̄i(t)) =
∑n
i=1 I(Ci = t, Ni1(t
−) = l, Ni2(t
−) = m)∑n












Upon substituting these estimates into (3.4), we obtain the weighted Breslow estimator of

























The limiting distribution of estimated regression coefficients are given by the following
theorem.
Theorem 3.4.1. Under regularity conditions, suppose Ĝ(t)/Ĝi(t) is a consistent nonpa-
rameteric estimate of G(t)/Gi(t), then
√
n(β̂k − βk) converges in distribution a zero-mean
normal random vector with a variance that can be consistently estimated by Î−1k Σ̂kÎ
−1
k ,









n(β̂2−β2), . . . ,
√
n(β̂K−βK)) converges in distribution to a zero-mean multivariate normal random vector








m , l,m = 1, . . . , K.
Remark 3.4.2. The weight function G(t)/Gi(t) is estimated nonparametrically and there
is no specific model assumption for the censoring process; therefore, the proposed approach
is relatively robust with respect to the censoring process.
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Remark 3.4.3. The global estimate of treatment β̂c is simply a linear combination of all
component-specific estimates of treatment effect, i.e., β̂c = c(β̂)
′β̂, where β̂ = (β̂1, . . . , β̂K).
The weight c(β̂) = Σ̂(β̂)−1Ĵ[Ĵ′Σ̂(β̂)−1J]−1 is chosen to estimate the weight matrix to mini-
mize the variance in the class of all linear estimators; Σ̂(β̂) is the estimate for the variance-
covariance matrix of β̂ given in Remark 3.4.1, and J = (1, ..., 1)′. An asymptotically equiv-
alent combined estimate can be obtained by fitting a single Cox model by stratifying on event
type and constraining the coefficients to be the same for the type types of events (Therneau
and Grambsch, 2000).
Remark 3.4.4. The variance estimator is the usual robust sandwich estimator that can
be directly obtained from R/S-PLUS or SAS using a suitably constructed dataframe in the
counting process format that properly takes into account of the weights.
3.5 Empirical Investigation
Simulation studies were conducted to assess the finite-sample performance of the estimators
obtained through the IPCW marginal estimating equations. The failure times T1 and
T2 were generated using a Clayton copula with exponential margins given the treatment
assignment. Without loss of generality we set C† = 1. For a given value of the association
parameter φ, λ1 and λ2 were determined to give a a particular stochastic ordering q =
P (T1 < T2|z = 0) and rate of administrative censoring p for T = min(T1, T2) (i.e. P (T <
C†) = p).
We define the intensity for the random censoring time according to (3.3) with λc0(t) = λ
c
0.
For given (α1, α2)
′, λc0 is specified to ensure a prescribed probability of observing the first
event in the control arm P (T1 < C|z = 0) = π is satisfied. We set β1 = β2 = log 0.80,
τ = 0.4 and varied q = P (T1 < T2|z = 0) over 0.25, 0.50 and 0.75. We set α1 = log 1.3 and
α2 = log 3.5 and set λ
c
0 so that P (T1 < C|z = 0) = 0.4. The regression coefficients were
obtained by solving (3.4) and (3.5) to obtain unweighted estimates and (3.14) to obtain
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weighted estimates with G(t) = 1 or more generally. The global estimate β̂c is a pooled
estimate of β̂1 and β̂2
Table 3.1: Empirical results from simulation studies examining the frequency properties
of estimators of the marginal regression coefficients and global estimators under
dependent censoring with β1 = β2 = log(0.8).
P (T1 < T2|z = 0)
0.25 0.50 0.75
Event Weight BIAS ESE ASE BIAS ESE ASE BIAS ESE ASE
Type 1 None 0.015 0.145 0.146 0.006 0.141 0.140 0.000 0.136 0.134
IPCW 0.001 0.172 0.172 -0.003 0.184 0.173 -0.004 0.168 0.159
IPCW† 0.003 0.152 0.153 0.000 0.151 0.147 -0.000 0.142 0.138
Type 2 None 0.008 0.114 0.113 0.004 0.130 0.129 0.000 0.151 0.154
IPCW 0.009 0.116 0.117 0.005 0.144 0.143 0.001 0.180 0.179
IPCW† 0.009 0.113 0.113 0.004 0.130 0.129 -0.000 0.151 0.153
Global None 0.011 0.109 0.110 0.005 0.116 0.117 0.001 0.122 0.122
IPCW 0.006 0.120 0.121 0.002 0.140 0.143 -0.001 0.146 0.141
IPCW† 0.007 0.112 0.113 0.003 0.122 0.120 -0.000 0.126 0.125
† estimate obtained by inverse probability weighted estimating equations with stabilized
weights
The summary statistics of the estimated regression coefficients are reported in Table
3.1 including the empirical bias (Bias), the empirical standard error (ESE), and the aver-
age robust standard error (ASE) based on the large sample results. The simulations were
conducted with 2000 samples each of n = 500 individuals. There is generally very good
agreement between the empirical and average asymptotic standard errors in all settings.
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While the biases are generally quite small in the unweighted analyses, it is apparent that
the impact of dependent censoring is different for the two marginal parameters and the
magnitude of bias is influenced by both the stochastic ordering of the events as well as the
(α1, α2)
′ parameters. That is, the bias is greater for type 1 events since the dependence
between the time of the type 2 event and censoring is greatest (this is what induces the
dependent censoring from marginal analyses of type 1 events). The empirical biases of
the weighted estimators are generally smaller indicating the advantages of inverse weight-
ing. The estimates obtained using the weight 1/Gi(t) have considerably larger standard
errors than the estimates obtain using the stabilized weight G(t)/Gi(t), which are in turn
much closer to the standard errors of the unweighted analyses. Thus the weight function
G(t)/Gi(t) leads to estimator with the best performance in that it provides protection
against dependent censoring at the price of a relatively small increase in the standard
error.
3.6 Application
Here we consider data from a trial of 244 breast cancer patients with skeletal metastases.
The experimental treatment is a bisphosphonate which is studied for its palliative effect of
reducing the incidence of fractures and the need for radiotherapy for the treatment of bone
pain. Following randomization patients were followed for up to 24 months. To address
the issue of the competing risks of death we adapt the marginal analyses to be based on
fracture-free survival and radiation-free survival. An alternative approach is to consider the
competing risks of death by including it as the third endpoint. In this case, the marginal
approach of WLW is still applicable (Wei and Glidden, 1997), where it is based on a model
for the cause-specific hazard for non-fatal events and model the ordinary hazard for death.
We did not explore this alternative in this study.
Figure 3.2 gives plots of the cumulative intensity for censoring by fracture status (left
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AT  LEAST  ONE  ROUND  OF  RADIOTHERAPY
Figure 3.2: Plot of cumulative intensity function for censoring by fracture status (left) and
radiotherapy status (right) for patients in the placebo arm.
panel) and radiotherapy status (right panel). The slope of the cumulative intensity for
censoring following the occurrence of the first fracture is considerably steeper than it is for
fracture-free individuals, revealing a dependence between fracture status and censoring.
The same pattern is seen in the right panel in that the rate of censoring for patients who
have had one round of radiotherapy is higher (reflected by the steeper slope) than those
who have not required radiotherapy. These plots are suggestive of a need to deal with
dependent censoring for marginal analyses.
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The estimates of the cumulative baseline hazard for the analysis based on fracture-free
survival and radiotherapy-free survival are given in Figure 3.3. There is empirical evidence
of a greater effect of dependent censoring in the fracture-free survival analysis in that
there is a bigger difference between the unweighted and weighted estimates than is seen for
the radiotherapy-free survival analysis. This is compatible with the simulation results in
that the larger difference between the cumulative intensities for censoring by radiotherapy
status in Figure 3.2 (in comparison to the estimators of the censoring intensity by fracture
status), suggests the dependence between censoring and radiotherapy is greater. This in
turn will have a greater effect on the estimates related to the fracture-free survival endpoint.
While the effects are not large, there is a suggestion that the unweighted analysis yields a
conservative estimate of the event rates since the naive estimate is lower than either of the
weighted estimates.
Table 3.2 contains the results of the marginal and global regression analyses. Here we
see the estimates of the treatment effect from the use of stabilized weights are slightly larger
than those obtained from an unweighted analysis. The relative risk reduction for fracture-
free survival was 22.6% for the unweighted analysis compared to a 24.9% relative risk
reduction from analysis using stabilized weights. Moreover, in contrast to the unweighted
analysis, the results based on the stabilized give statistically significant evidence of a treat-
ment benefit for fracture-free survival (p= 0.0465). Very similar estimates are seen for the
radiotherapy-free survival endpoint for unweighted and weighted analyses using stabilized
weights. Finally, use of the stabilized weights incurs a relatively small penalty in terms of
efficiency as the standard errors are very close to those of the unweighted analyses. For
the global analysis, there is a 32.3% relative risk reduction from the unweighted analysis
and a 33.2% reduction from the weighted analysis using stabilized weights.
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Table 3.2: Estimates obtained by fitting separate marginal Cox models and using the
global Wei-Lin-Weissfeld analysis in the analysis of data from the trial of breast cancer
patients with skeletal metastases; unweighted and weighted analyses.
Endpoint Weight EST SE HR 95% CI p−value
Fracture None -0.256 0.142 0.774 (0.586,1.023) 0.0714
IPCW -0.483 0.188 0.617 (0.427,0.891) 0.0100
IPCW† -0.286 0.144 0.751 (0.567,0.996) 0.0465
Radiation None -0.547 0.152 0.579 (0.430,0.780) 0.0003
IPCW -0.505 0.158 0.604 (0.442,0.823) 0.0014
IPCW† -0.550 0.154 0.577 (0.426,0.781) 0.0004
Global None -0.393 0.104 0.675 (0.551,0.827) 0.0002
IPCW -0.493 0.144 0.611 (0.461,0.810) 0.0006
IPCW† -0.404 0.125 0.668 (0.523,0.853) 0.0012
† estimate obtained by inverse probability weighted estimating equations with stabilized
weights
3.7 Discussion
Multivariate failure time data are frequently encountered in clinical trials and observational
studies. Frailty models are popular choice for the analysis of multivariate failure time data,
but they do not yield estimates of treatment effect which have a simple marginal inter-
pretation. Such models can be formulated using copula functions, but it is undesirable to
base inferences on a particular parametric model and for this reason the marginal methods
proposed by Wei et al. (1989) are preferred. Inference regarding regression coefficients in
this framework are carried out by use of a robust sandwich-type variance estimate easily
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computed in SAS or R/S-PLUS (Therneau and Grambsch, 2000).
With multivariate failure time data, studies are usually designed to follow individuals
for the occurrence of all types of events up until some administrative censoring time. In this
setting however, event occurrence may cause investigators to withdraw patients from a trial
if it is thought that following the protocol is no longer in the patients’ best interests. This
can occur, for example, when one or more clinical endpoints are observed. The simplicity of
the marginal analysis of Wei et al. (1989) arises from the working independence assumption.
This enables the use of standard software for point estimation, but the validity of this hinges
on the censoring being independent of the event processes. When this is not satisfied
inconsistent estimates are obtained for all marginal parameters including the cumulative
baseline hazard functions and the regression coefficients from the marginal Cox models.
Use of inverse probability of censoring weights are known to address this problem (Robins,
1993) and we have shown that this strategy can be put to good use in the context of
multivariate failure time data. In this study, we proposed a marginal IPCW approach to
analyze multivariate failure times with event-dependent censoring and demonstrated the
effectiveness of the proposed approach using simulation studies and in a breast cancer trial
for patients with skeletal metastases.
3.8 Appendix
3.8.1 The Limiting Value of Unweighted Estimators
The numerator of (3.8), E(Ȳik(t)dNik(t)), is calculated by noting
E(Ȳik(t)dNik(t)) = EZi{[EȲik(t)|ZiE(dNik(t)|Ȳik(t), Zi)]}





P (Zi = z)P (dNik(t) = 1, Ȳik(t) = 1|Zi = z)
In the same way, the denominator E(Ȳik(t) exp{βzi}) can be obtained as
1∑
z=0
exp(βkz)P (Zi = z)P (dNik(t) = 1, Ȳik(t) = 1|Zi = z) .
The probabilities P (Ȳik(t) = 1|zi = z) can be obtained analytically under the marginal
models, Clayton copula and event-dependent censoring mechanism (3.3). Hence the lim-
iting value of the estimator of the baseline cumulative hazard function dΛ∗0k(t) can be
obtained. The limiting value of estimators of the regression coefficients are obtained fol-
lowing these calculations from (3.9).
3.8.2 Proof of Theorem 3.4.1
The following derivations are provided in the context of a more general marginal Cox
model with a vector of time-varying covariates, and we suppress the dependence on the
type of event, k. For a random sample of n subjects, the observed data consist of




and s(k)(β, t) = E(S(k)(β, t)), where k = 0, 1, 2 and a⊗0 = 1, a⊗1 = a, and a⊗2 = aa′. We








{Zi(t)− Z̄(β0, t)}⊗2Yi(t)wi(t)/(nS(0)(β, t))dNi(t) .
Here we assume administrative censoring at C† and impose the following regularity condi-
tions:
1. P (Ci ≥ C†) > 0, i = 1, . . . , n;
2. Ni(C





|dZji(t)| ≤ K for all j = 1, . . . , p and i = 1, . . . , n, where Zji is the jth
component of Zi and K is a constant.
4. I = E
[∫ C†
0
{Zi(t)− z̄(β0, t)}⊗2Yi(t)wi(t) exp{Z ′i(t)β0}dΛ0(t)
]
is positive definite.
5. In = I + op(1).
Proof. We first establish the asymptotic normality of
√
n(β̂ − β0) using the true weight
function wi(t) = G(t)/Gi(t), and then prove that the effect of using a nonparametric
estimation of wi(t) can be ignored in the variance estimation. Consider the weighted Cox






wi(u)Yi(u){Z ′i(u)β − logR(β, u)}dNi(u), (3.15)
where R(β, u) = nS(0)(β, u). By Lemma A2 of Hjort and Pollard (Hjort and Pollard,
1993), we can expand logR(β, u) around the true value β0
logR(u, β0 + x)− logR(u, β0) = Z̄ ′(u)x+
1
2
x′V (u)x+ ν(x, u), (3.16)
where V (u) =
∑n
i=1wi(u)Yi(u) exp{Z ′i(u)β0}{Zi(u) − Z̄i(u)}⊗2/R(β0, u). The reminder
term ν(u, x) is bounded by 4
3
maxi≤n |(Zi(u)− Z̄(u))′x|.



















































(2K)3|t|3n− 32dNi(u) where K is the absolute bound on
the covariates. The latter term is O(n−
1
2 ) and goes to zero as n → ∞. Hence, (3.17) can
be approximated by U ′nt − 12t
′Int, which can be maximized at t = I
−1
n Un. Note that its
concavity in t follows from the convexity of logR(β, u) in β. Suppose β̂ is solution to the
estimating equation (3.14) that maximizes the log partial likelihood (3.15), then
√
n(β̂−β0)
maximizes (3.17). By the assumption 5 and the extension of the Basic Corollary of Hjort
and Pollard (1993), we can show that
√
n(β̂ − β0) = I−1Un + op(1), (3.19)
and the asymptomatic normality of β̂ can be established if the asymptomatic normality of
Un is established.

























Zi(u)dMi(u). For fixed time t, M̄(t)





2M̄Z(t)) converges in finite dimensional distribution to a zero-mean
Gaussian processes (WM,WMZ ). Note that Mi(t) is the difference of two monotone func-
tions. The bounded variation assumption 3 implies that Zi(·) is bounded and we may
72
assume without loss of generality that Zi(·) ≥ 0; otherwise Zi(·) can be written as dif-




Zi(u)dMi(u) is also a difference of two monotone functions in t.
Therefore, by the weak convergence of the monotone class as in the example of 2.11.16




2M̄Z(t)) is tight and converges weakly
to (WM,WMZ ) and it can be verified that both satisfy Kolmogorov-Chentsov criterion
(e.g. Corollary 16.9 in Kallenberg (2010)) so that they have continuous sample path with
respect to the Euclidean distance.
By the Skorokhord strong embedding theorem (Shorack and Wellner (1986), pages 47-






(0)(β0, t)) converges almost surely to (WM ,WMZ , s(1)(β0, t), s(0)(β0, t)). Note
that Zi(·) ≥ 0 (i = 1, . . . , n) is a monotone function by assumption and 1/Gi(t) is nonneg-
ative and nondecreasing function in t; therefore, S(0)(β0, t) and S
(1)(β0, t) are nonnenegative















uniformly in t almost surely. Combining this result with the convergence of n−
1
2M̄Z to




surely in the new probability space and thus weakly in the original probability space. This
limiting Gaussian process has covariance function









0 ≤ s, t ≤ C†, between times s and t. Then by the Basic Corollary of Hjort and Pol-
lard (1993),
√
n(β̂ − β0) converges in distribution to a multivariate normal distribution
MVN(0, I−1ΣI−1).
We now prove that the nonparametric estimation of the weight function wi(t) can be
ignored in the variance estimation. Note that the weight wi(t) is a generic weight function
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W (·) evaluated at time t based on the history Hi(t) of subject i, where H(t) is defined
in Section 3.2.1. Therefore, we can write wi(t) = W (t,Hi(t)). We then suppress the
arguments of the function W for notational convenience. Let U(Ni(t), Yi(t), β,W ) be the
partial score functions corresponding to (3.14). Then EH(t)(U(Ni(t), Yi(t), β0,W0) = 0 for
true value β0 and the true weight function W0 as showed in Section 3.4.1. The estimating





U(Ni(t), Yi(t), β, Ŵ ) = 0 (3.22)
for β, by plugging in a nonparameteric estimate Ŵ . Here the Ŵ is obtained by a strat-
ified Kaplan-Mierer estimator. Note that the partial score function U(Ni(t), Yi(t), β,W )
is obtained by ∂L(Ni(t), Yi(t), β,W )/∂β, where L(·) is the log partial likelihood function
in (3.15). By using the accumulated Kullback-Leiber information for partial likelihood
functions as in Wong (1986), we can show that the true weight function W0 maximizes
EH(t)(L(Ni(t), Yi(t), β,W )) over the set of weight functions W , where EH(t)(·) is the ex-
pectation taken with respect to the history H(t). This indicates that the criterion of 3.11
in Newey (1994) is satisfied. Therefore, by the Proposition 2 of Newey (1994), the nonpara-
metric estimation of the weight function Ŵ can be ignored in calculating the asymptotic
variance of β̂; that is, the variance estimate will be the same as if Ŵ = W0.
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Chapter 4




Clinical trials must be designed with appropriate power to address scientific needs, ethical
demands, and financial restrictions. In parallel group randomized trials involving failure
time outcomes, power objectives are typically met for a given model (e.g., Cox model) by
specifying the event rate in the reference arm, the clinically important effect, the censoring
rate and the size of the test, and then by deriving a suitable sample size based on large
sample theory (Andersen et al., 1993). Under this general framework, a number of authors
have developed methods for planning trials based on analyses of the time to the first event
(George and Desu, 1974; Freedman, 1982; Schoenfeld, 1983; Lachin and Foulkes, 1986).
Sample size formulae have been developed (Cook, 1995) for recurrent event outcomes
based on mixed Poisson models with multiplicative rate functions (Lawless and Nadeau,
1995; Cook et al., 1996). Power and sample size considerations were subsequently developed
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for more general multiplicative models (Bernardo and Harrington, 2001) using counting
process theory e.g., Fleming and Harrington (1991). Another approach to the analysis
of recurrent event data in clinical trials is to use the robust methods for the analysis of
multivariate survival data (Wei et al., 1989) under a working independence assumption
and sample size formula for this approach are available (Hughes, 1997). More recently
there has been interest in trial design based on covariate-adjusted log-rank statistics for
recurrent event analyses and associated sample size formula have been developed (Song
et al., 2008).
To date no methods have been developed for the design of clinical trials in which the
aim was to test treatment effects on recurrent and terminal event processes. We address
this problem under the framework of a Markov model with transient states corresponding
to the recurrent events and a single absorbing state for death. The treatment effect on
the recurrent events is formulated by specifying multiplicative intensity models with time-
dependent strata based on the cumulative event history and a common treatment effect;
this formulation is in the spirit of the Prentice et al. (1981) approach to the analysis of
recurrent events. Multiplicative intensity-based models are also incorporated for mortality
with the same stratification criteria. Under this formulation we derive the limiting value of
partial score statistic for the treatment effect on the recurrent and terminal event processes,
along with the asymptotic variances under the null and alternative hypotheses. Sample
size criteria are then obtained to satisfy power objectives for both types of events.
We consider design issues when it is of interest to demonstrate either superiority or
non-inferiority of an experimental treatment when compared to an existing treatment for
both the recurrent event process and the survival process. Non-inferiority designs are
being adopted with increasing frequency in cancer and cardiovascular research (Rothmann
et al., 2003; Kaul et al., 2006) since many treatments with proven efficacy are available and
hence placebo-controlled trials are not ethical. In such settings new interventions would
need to have some advantages such as reduced cost, a better adverse event profile, or less
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invasive administration (D’Agostino et al., 2003). Rothmann et al. (2003) provides an
excellent discussion about the various approaches to hypothesis testing in the context of
non-inferiority oncology trials and extensions have recently been made for recurrent event
analyses based on mixed Poisson models or robust marginal methods (Cook et al., 2007).
4.1.2 Trial Design for Patients with Skeletal Metastases
Cancer patients with skeletal metastases are at increased risk of a variety of clinical
events including pathological and nonpathological fractures, bouts of acute bone pain,
and episodes of hypercalcemia. These events are typically grouped together to form a
composite recurrent “skeletal related event” which is used as a basis for the evaluation of
treatments designed to reduce the occurrence of skeletal complications in cancer patients to
help maintain functional ability and quality of life and minimize health service utilization
(Hortobagyi et al., 1998). Because the patient population has metastatic cancer, they are
also at considerable risk of death. In breast cancer, twelve month survival in recent studies
has been approximately 78.9% in treated patients; in lung, prostate and other solid tumors
the 12 month survival rates were 28.0%, 66.0% and 33.6% respectively.
While bisphosphonate therapy is palliative and not expected to impact survival, an
assessment of the effect on survival times is warranted for a complete evaluation of the con-
sequences of treatment. Simultaneous consideration of treatment effects on the recurrent
skeletal related events and survival is therefore essential and analyses must accommodate
a possible association between the recurrent event and terminal death process.
4.2 Likelihood for Recurrent and Terminal Events
We adopt the framework of a continuous time multistate Markov process to jointly model
the recurrent events and terminal event. Let {Zi(s), 0 < s} denote this process for indi-
vidual i with a countable number of states in the state space S = {0, 1, . . . , D} and a right
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continuous sample path. The integers 0, 1, 2, . . . represent the number of recurrent events
experienced over time and D represents an absorbing death state. Figure 4.1 displays a
multi-state diagram for the recurrent events and terminal event process. If individual i
is alive at time t and has experienced precisely j events over (0, t], then Zi(t) = j and if
individual i dies at time s, Zi(t) = D for t ≥ s. We assume that all subjects are at state
0 at time t = 0, the time of randomization. Let vi be a binary treatment indicator for
individual i such that vi = 1 if individual i was randomized to the experimental treatment
and vi = 0 otherwise.
Let Tij be the time individual i enters state j, j = 1, . . . , and T
d
i their time of death,
i = 1, . . . ,m. Let dNij(t) = I(Zi(t
−) = j − 1, Zi(t) = j), indicate that a (j − 1) → j
transition was made at time t for individual i, so dNij(t) = 1 at tij but is zero otherwise,
j = 1, . . . . Let dNdij(t) = I(Zi(t
−) = j − 1, Zi(t) = D) indicate that a (j − 1) → D
transition is made at time t (i.e. that the jth event was death). Let Ni(t) = (Nij(t), j =
1, . . .) and Ndi (t) = (N
d
ij(t), j = 1, . . .) jointly be the multivariate counting process for
individual i. The history of the process is the information observed up to t− and we let
Hi(t) = {Ni(s), Ndi (s), 0 ≤ s < t, vi} denote the history for individual i, i = 1, . . . ,m.
A stochastic model for this multistate process must be assumed for to derive sample size
calculations. We formulate this model by specifying the respective intensity functions
(Cook and Lawless, 2007). The intensities for event occurrence or death are defined as
λj(t|Hi(t)) = lim
∆t↓0





P (∆Ndij(t)) = 1|Zi(t−) = j − 1, Hi(t))
∆t
,
respectively, where ∆Nij(t) = Nij((t + ∆t)
−) − Nij(t−) and ∆Ndij(t) = Ndij((t + ∆t)−) −
Ndij(t
−) count the number of the (j − 1)→ j and (j − 1)→ D transitions over (t, t+ ∆t)
respectively.
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Consider a study with planned follow-up over the interval (0, τ ], where τ is called
the administrative censoring time. Individuals may withdraw prematurely from a study
and so we let τ †i be the random right censoring time and let τi = min(τ
†
i , τ) be the net
censoring time for individual i; we let Xi = min(T
d
i , τi) denote the total time on study and
δi = I(Xi = T
d
i ) indicate whether the terminal event was observed. Let Yi(t) = I(t ≤ τi)
indicate whether individual i is under observation at t and Yij(t) = I(Zi(t
−) = j − 1), j =
1, . . . indicate that individual i is at risk of a transition out of state j−1 at time t (i.e. they
are at risk for the jth event of either type), so Ȳij(t) = Yi(t)Yij(t) indicates they are both





are so-called the observable counting processes for the recurrent event and terminal events
respectively. The observed data can then be written {dN̄i(s), dN̄di (s), Yi(s), 0 < s, vi},
i = 1, . . . ,m. The history of the observable process is the information observed up to t−
and denote H̄i(t) = {N̄i(s), N̄di (s), Ȳi(s), 0 ≤ s < t, vi}, i = 1, . . . ,m.
Under conditionally independent censoring, the intensities for event occurrence and
death of the observable processes are given by λ̄j(t|H̄i(t)) = Ȳij(t)λj(t|Hi(t)) and γ̄j(t|H̄i(t)) =
Ȳij(t)γj(t|Hi(t)), respectively. Thus if individual i experienced Ji > 0 recurrent events at














where ti0 = 0 and for notational convenience we let ti,Ji+1 = Xi.
A specification is required for the intensity functions and here we adopt a multiplicative
intensity Markov model (Andersen et al., 1993) and we set the two intensities to
λ̄j(t|H̄i(t)) = Ȳij(t)λj(t) = Ȳij(t)λ0j(t) exp(βvi) , (4.2)
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Figure 4.1: State space diagram for recurrent and terminal events representing the model
formation based on counting processes; λ0j(t)e
βνi , j = 1, 2, . . . , are transition intensities
for the recurrent events from state (j − 1) to state j and γ0j(t)eθνi , j = 1, 2, . . . , are the
event-dependent transition intensities from (j − 1) state to death; state Dj represents
death after the jth event.
and
γ̄j(t|H̄i(t)) = Ȳij(t)γij(t) = Ȳij(t)γ0j(t) exp(θvi) , (4.3)
where λ0j(t) and γ0j(t) are non-negative baseline intensity functions for the recurrent event
and terminal event for state j, respectively. Through the time-dependent stratification on
the cumulative number of events, this model accommodates an association between the
recurrent and terminal events. The multiplicative effect of vi is assumed to be constant
(i.e. not event dependent) for the two processes to give a parsimonious parameterization of
the treatment effect. This model was discussed by Prentice et al. (1981) and is sometimes
referred to as the stratified Andersen-Gill model (Andersen and Gill, 1982).
The likelihood (4.1) can be factored into two parts, one part involving β and the other
part involving θ. Under (4.2), the likelihood contribution for the recurrent event process
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λij(u)du is the cumulative intensity function for individual i in stratum
j. The partial likelihood for a sample of size m is then the product of m such terms.











































i exp(βvi) and a = 0, 1. Similarly, we obtain the

























i exp(θvi) and a = 0, 1. The score functions (4.7) and
(4.8) are those of a stratified Cox regression model with one binary covariate. These two
score functions form the basis of partial score statistics we used to calculate sample size.
4.3 Asymptotic Properties of Partial Score Statistics
In this section, we investigate the asymptotic properties of the partial score statistic (4.7)
and (4.8) under the null and the alternative hypotheses. We suppose here that analyses are
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to be based on at most J events, but note that J can be chosen to be large enough to capture
all events in any given setting with probability approaching one. Suppose the treatment
effect is β0 in (4.2) under the null hypothesis and βA under the alternative hypothesis.
Under regularity conditions A to D of Andersen and Gill (1982) and the assumption that

















dM rij(u) , (4.9)
where E0(·) is the expectation taken under the null hypothesis and
dM rij(u) = dN̄ij(u)− Ȳij(u) exp(β0vi)dΛ0j(u) (4.10)
is the associated martingale under the null. Note that (4.9) is a sum of m independent
and identically distributed random variables with expectation zero, so it follows from the
central limit theorem that m−
1
2 times (4.9) converges in distribution to a zero-mean normal




















j (β0, u) = E0[R
(a)
j (β0, u)], a = 0, 1, 2. This asymptotic variance is similar to the
expected information from a stratified Cox regression where the strata are defined by the
state of the Markov process.
Under the same set of regularity conditions as under the null hypothesis, the partial

















under the alternative hypothesis, where the expectation is taken under the alternative
hypothesis. Note that (4.12) is also a sum of m independent and identically distributed
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random variables and it follows from the central limit theorem that m−
1
2 times (4.12)





























the asymptotic variance of m−
1












Thus we have expressions for EA(m
− 1
2U(β0)) by (4.12), the asymptotic variance V0 =
Var0(m
− 1
2 U(β0)) of the score statistic under the null by (4.11), and the asymptotic variance
of VA = VarA(m
− 1
2 U(β0)) under the alternative by (4.14). These results will be used for
the sample size calculations in the next section. Details on how the requisite expectations
can be carried out are given in the appendix.
For the terminal event under the null hypothesis, m−
1
2 times the partial score statistics




























γ0j(u)du is the baseline cumulative intensity function for the terminal event in
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under the null, where s
(a)
j (θ0, u) = E0[S
(a)
j (θ0, u)], a = 0, 1, 2, and under the alternative
hypothesis, m−
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under the alternative, where








4.4 Sample Size Derivation Based on Partial Score
Statistics
4.4.1 Sample Size for the Design of Superiority Trials
In this section, we adopt a score test based on the partial score statistics described above to
calculate sample size requirements for a clinical trial involving recurrent events and terminal
event. We illustrate this procedure by testing a treatment effect on the recurrent events.
In superiority trials interest is in demonstrating a new therapy for both the recurrent event
process and the terminal event. In particular, we consider the case where H0 : β = β0 and
HA : β 6= β0, where β0 is the null value, and βA < β0 is the value under the alternative
that represents the minimal clinically important treatment effect we wish to detect for
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the recurrent event process. If we assume a follow-up period (0, τ ], then under the null





which converges in distribution to a standard normal random variable.
The approximate one-sided 100α1% level partial score test involves rejecting the null if
Z < zα1 , where zα is the 100α% percentile of the standard normal distribution. Under the
alternative hypothesis, if we set the power to 100(1− α2)%, we require P (Z < zα1|HA) =
1− α2. Straightforward calculations show that the required sample size m to detect the
effect of a reduction in the intensity of events under the new treatment at the significance











where Ui(·) is the contribution of a single individual i to the partial score statistic (4.7).
Similarly, the required sample size for detecting superiority of the treatment on the











Then the minimum required sample size to detect the superiority of the new treatment on
both the recurrent events and terminal event is max(m,md).
4.4.2 Sample Size for the Design of Non-Inferiority Trials
In this section we address design issues when testing for non-inferiority of a new treatment
for both recurrent events and terminal event when compared to a existing active-control.
We adopt common notation to formulate the non-inferiority hypotheses (Cook et al., 2007).
Let LRR(C1/P1) denote the log-relative risk reflecting the effect of the active-control (C)
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to a placebo (P ) treatment on the risk of events. The subscript ‘1’ on C1 and P1 to denote
that this estimate must be known or estimated from historical studies. Similarly, we let
LRR(C2/P2) denote the effect of the active-control to a placebo in the context of planned
study. We also let LRR(E2/P2) denote the log-relative risk for the planned new treatment
versus a placebo. Though no placebo will be used in the planned study, it is helpful to
make indirect comparisons with the effect of the active-control to placebo. In particular,
the non-inferiority trial is intended to show that the experimental trial retains a prestated
percentage of the active-control effect against placebo with a specified power and type I
error rate. We formulate the non-inferiority hypotheses for the recurrent events as follows.
Let δ0 be the percentage of the active-control effect to placebo necessary to retain for
non-inferiority claims for the new treatment. The null hypothesis can be formulated as
H0 : LRR(E2/C2) ≥ (1− δ0)LRR(P1/C1) (4.22)
which is to be tested against the alternative hypothesis
HA : LRR(E2/C2) < (1− δ0)LRR(P1/C1). (4.23)
For the purpose of sample size calculation, it is sometime desirable to consider a par-
ticular value of LRR(E2/C2) in the alternative hypothesis, which may be expressed as a
percentage of the effect of active-control to the placebo. We let 1−δA denote the percentage
of the active-control effect that the experiment treatment retains once the null hypothesis
is rejected so that LRR(E2/C2)=(1-δA)LRR(P1/C1)< (1− δ0)LRR(P1/C1). In this study,
we examine different values of δA in sample size calculations.
For testing non-inferiority of the treatment based on the recurrent event, we let β =
LRR(E2/C2) and β0=LRR(P1/C1) and evaluate the partial score statistic (4.7) at the
boundary of the null hypothesis of (4.22). If we further suppose that the follow-up duration





then converges in distribution to a standard normal random variable Z, where V0(·) is the
asymptotic variance of the partial score statistics under the null hypothesis according to
(4.11). Based on a one-sided α1 level partial score test, to reject the null hypothesis with
the power 1−α2, one can obtain the required sample size m for a partial score test to test
non-inferiority of the new treatment on the recurrent events as
(z1−α1
√





where VA(·) is the asymptotic variance of the partial score statistic under the alternative
hypothesis (4.14) and Ui(·) is the contribution of individual i to the partial score statistic
(4.7). The expectation EA(·) is taken with respect to the true model under the alternative
as in (4.9) with βA = (1 − δA)β0. The required sample size md for testing non-inferiority
of new treatment on the terminal event may be obtained by replacing the corresponding









where V d0 (·) and V dA(·) are the asymptotic variances for the partial score statistics for the
terminal event under the null and the alternative hypotheses, respectively; the expectation
EA is taken with respect to the true model for the terminal event under the alternative
with θA = (1− δA)θ0.
The minimum requirement for testing the non-inferiority of the new treatment on both
recurrent events and terminal event is max(m,md) for one-sided test with the level of α1
and the power of 1− α2.
4.5 An Empirical Study of Frequency Properties
We simulate the Markov process with the multiplicative model of (4.2) for recurrent events
and (4.3) for the terminal event. For planning purposes we set an upper limit to the number
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of states and set the maximum number of events to J = 10; only approximately 2% patients
had eight or more skeletal complications in Hortobagyi et al. (1996). For computational
convenience, we further specify the intensity function for recurrent event (4.2) and for
the terminal event (4.3) as λ0j(t) = λ0 exp(ψβ · (j − 1)) and γ0j(t) = γ0 exp(ψθ · (j − 1))
j = 1, . . . , 10, respectively. The constants ψβ and ψθ represent the relative increase in the
event and death intensity with the occurrence of each additional event. In the simulation
study, we consider ψβ = 1.0 for constant baseline intensity (rate) which is independent of
the number of previous events and ψθ = 1.0 to correspond to the setting where mortality
is independent of event occurrence. We set ψβ = 1.1 to reflect the setting where the event
intensity increases with each event and ψθ = 1.1 to correspond to the case where the
mortality rate increases with event occurrence. The coefficients β and θ are the effects of
the experiment treatment on recurrent events and death, respectively, and are chosen to
represent modest improvements.
The Markov model has twelve states (0, 1, . . . , 10) corresponding to the cumulative
number of recurrent events and one absorbing state for death; we number these states
1 to 12 and consider a 12 × 12 transition intensity matrix denoted Qv for an individual
with vi = v having (k, `) entry q
v
kl given by λ0k exp(βv) for k = 1, . . . , 10 and ` = k + 1,
γ0k exp(θv) for k = 1, . . . , 10 and ` = 12, −(λ0k exp(βv)+γ0k exp(θv)) for k = ` = 1, . . . , 10,
and zero otherwise. The transition probability matrix has elements P`k(t|v) = P (Z(t) =
`|Z(t−) = k, v) and can be obtained as described in the appendix. We further specify the
baseline intensities λ0 and γ0 by setting the probabilities that for a control subject the first
event is a recurrent event to q = λ0/(γ0 + λ0) and setting the probability that a control
subject has died by t = 1 to q for some pre-specified values of p and q.
4.5.1 Empirical Study of Superiority Designs
For simulation studies involving superiority designs, under the null hypothesis of no treat-
ment effect we set β0 = θ0 = 0. Under the alternative we set βA = log 0.8 and θA = log 0.9.
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The duration of the study is set to τ = 1. A random censoring time is simulated for each
individual using an exponential random variable with a probability of P (τi < 1) = 0.2.
We investigate the performance of the proposed methods for sample size calculations for
different scenarios. For each setting the sample sizes are determined according to formu-
lae in (4.20) and (4.21). All simulations were implemented in R, and the coxph function
in the survival package was used to obtain the partial score statistics. By setting the
iter.max and init options to zero, the partial score statistics are obtained using the func-
tion coxph.detail. Under the null hypothesis, the variance of partial score statistic was
obtained by summing up the observed information at each event time. Under the alterna-
tive, this variance was calculated using the sample variance of the partial score statistics
at each event time. For each setting, we conducted 2000 replicates and reported the per-
centage of those replicates leading to rejection of the null hypothesis as the empirical type
I error rate under the null hypothesis, and as the power under the alternative. Table 4.1
displays the empirical type I error rate and the power for different superiority settings. The
empirical type I error rates are consistent with the nominal level of 0.025. For testing for
superiority of a new treatment with respect to both the recurrent event and the terminal
event, max(m,md) was the sample size for the terminal event. The empirical powers are
consistent with the nominal level of 0.8.
4.5.2 Empirical Study of Non-Inferiority Designs
In this section we present simulation studies conducted to validate the proposed methods
for sample size calculations for testing non-inferiority of the experiment treatment on both
recurrent events and terminal event. We demonstrate that the empirical rejection rates are
consistent with the nominal levels. In particular, we set LRR(C1/P1)=log 0.6 (β0) for the
effect of active-control against a placebo for the recurrent events and LRR(C1/P1)=log 0.8
(θ0) for the terminal event. We also assume the constancy assumption so that LRR(P2/C2)=
LRR(P1/C1).
89
We consider the designs where the aim is to demonstrate that the experimental treat-
ment retains at least 50 per cent of the effect of the active-control, so that δ0 = 0.5. In this
simulation study, we consider one-sized test with nominal level of type I error rate α1=0.025
and the power is set to 80 per cent (1− α2=0.8). The effect of the experiment treatment
under the alternative hypothesis is represented by LRRA(E2/C2)=(1 − δA)LRR(P1/C1)
and we let δA = 0.90 and 1.00 to correspond to a retention of 90 and 100 per cent of
the active-control effect, respectively. The duration of the follow-up τ is set to be 1. A
random censoring process is simulated for each subject using an exponential distribution
with parameter ρ, which is specified so that each subject may withdraw from the study
with a probability of 0.20 (ρ = log 5/4).
For each simulation setting, the sample size is determined according to the formula
(4.25) and (4.26). The simulation was implemented in R and the partial score statistics are
obtained using coxph function in the survival package by setting the iter.max option
equal to zero. The partial score statistics was obtained by setting the init option as
(1−δ0)β0. Under the null hypothesis, the corresponding variance was obtained by summing
up the observed information of each event time. Under the alternative hypothesis, this
variance was calculated by the sample variance of the partial score statistics at all event
times.
We conducted 2000 replicates and the percentage of those replicates leading to rejection
of the null hypothesis is the empirical type I error rate under the null and the power under
the alternative. Table 4.2 presents the empirical type I error rate and the power for different
non-inferiority configurations. The empirical type I error rates are all consistent with the
nominal level of 0.025. The empirical powers are all close to the nominal levels for modest
and large sample sizes. For simultaneous detecting the superiority of a new treatment
on both recurrent events and the terminal event, max(m,md) equal to the sample size
calculated for the terminal event. The empirical powers for simultaneous testing for the
superiority are consistent with the nominal level of 80%.
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Table 4.1: Sample sizes and empirical rejection rates for tests of superiority for recurrent
and terminal events; β0 = θ0 = 0, βA = log(0.80) and θA = log(0.9); %REJ0 and %REJA
are the empirical type I error rate (2.5%) and empirical power (80%) respectively.
ψθ = 1.0 ψθ = 1.1
ψβ Endpoint
† Setting‡ m %REJ0 %REJA m %REJ0 %REJA
1.0 Recurrent θ = θ0 728 2.45 84.45 771 2.00 83.10
Recurrent θ = θA 710 2.65 84.20 753 2.40 82.90
Death β = β0 6636 2.40 80.35 6673 2.30 80.85
Death β = βA 6740 2.50 80.50 6816 2.75 80.50
1.1 Recurrent θ = θ0 691 2.85 84.70 737 2.40 84.25
Recurrent θ = θA 674 2.70 84.15 719 2.10 84.25
Death β = β0 6674 2.60 79.45 6691 2.25 81.15
Death β = βA 6759 2.45 80.50 6836 2.40 83.00
† Endpoint is the outcome used for the sample size calculation
‡ Setting is the value of the parameter for the complementary outcome when testing the
corresponding endpoint
91
Table 4.2: Sample sizes and empirical rejection rates for tests of non-inferiority for
recurrent and terminal events; β0 = θ0 = 0, βA = log(0.60), θA = log(0.8) and δ0 = 0.50;
%REJ0 and %REJA are the empirical type I error rate (2.5%) and empirical power (80%)
respectively.
1-δA=0.9 1-δA=1.0
Endpoint† Setting‡ m %REJ0 %REJA m %REJ0 %REJA
ψθ = 1.0 ψβ = 1.0 1− δA = 0.9
Recurrent θ = θ0 986 2.20 83.05
Recurrent θ = θA 967 2.20 83.50 962 2.40 83.60
Death β = β0 9665 2.65 81.20 6296 2.65 80.65
Death β = βA 9850 2.65 81.40 6405 2.55 81.40
ψθ = 1.0 ψβ = 1.0 1− δA = 1.0
Recurrent θ = θ0 664 2.55 83.70
Recurrent θ = θA 657 2.65 83.35 655 2.75 82.60
Death β = βA 9904 2.75 82.10 6429 2.85 81.85
ψθ = 1.0 ψβ = 1.1 1− δA = 0.9
Recurrent θ = θ0 945 2.65 84.30
Recurrent θ = θA 934 2.85 84.85 931 2.10 84.90
Death β = β0 9669 2.30 80.15 6276 2.30 79.10
Death β = βA 9860 2.25 82.35 6401 2.40 81.60
ψθ = 1.0 ψβ = 1.1 1− δA = 1.0
Recurrent θ = θ0 639 2.60 83.75
Recurrent θ = θA 631 2.90 84.40 629 2.30 84.70
Death β = βA 9918 2.20 82.20 6438 2.75 81.55
ψθ = 1.1 ψβ = 1.0 1− δA = 0.9
Recurrent θ = θ0 1042 2.15 82.50
Recurrent θ = θA 1030 2.25 83.05 1027 2.05 82.10
Death β = β0 9761 2.05 81.75 6322 2.65 80.05
Death β = βA 9964 2.05 80.50 6475 2.75 79.35
ψθ = 1.1 ψβ = 1.0 1− δA = 1.0
Recurrent θ = θ0 701 2.05 83.75
Recurrent θ = θA 693 2.65 83.65 691 2.65 82.70
Death β = βA 10029 2.75 79.55 6507 2.35 81.05
ψθ = 1.1 ψβ = 1.1 1− δA = 0.9
Recurrent θ = θ0 1004 2.85 84.25
Recurrent θ = θA 992 2.75 83.20 990 2.95 83.9
Death β = β0 9752 2.05 80.52 6329 2.50 80.70
Death β = βA 9986 2.25 80.30 6482 2.50 80.15
ψθ = 1.1 ψβ = 1.1 1− δA = 1.0
Recurrent θ = θ0 678 2.60 83.70
Recurrent θ = θA 670 2.35 84.70 665 2.75 83.65
Death β = βA 10053 2.35 79.75 6526 2.25 80.80
† Endpoint is the outcome used for the sample size calculation
‡ Parameter setting for the complementary outcome when testing the corresponding endpoint
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4.6 Trial Design in Cancer Metastatic to Bone
Hortobagyi et al. (1996) report on the effectiveness of the bisphosphonate pamidronate for
the prevention of skeletal related events in breast cancer patients with skeletal metastases.
Here we report on analyses of this data to furnish information helpful for the design of a
future study planned to have one year duration.
Figure 4.2 displays the estimates of the cumulative transition intensities for the placebo
group for both event occurrence and death. Separate transition intensities were specified
for the first to third events (i.e., λ̄(t|H̄i(t)) = Ȳij(t)λ0j(t) where Ni(t−) = j, j = 0, 1, 2),
but the baseline intensity was assumed to be the same for fourth and subsequent events
due to sparse data (i.e., λ̄(t|H̄i(t)) = Ȳij(t)λ∗03(t) if Ni(t−) = j ≥ 3. The risk of the
first event appears roughly constant over two years and could be represented with a time
homogeneous rate of λ0 = 1 with time measured in years. The slope of the Nelson-
Aalen estimates for the event intensities (left panel) are increasing with event occurrence
indicating increased risk of future events with each event occurrence. For design purposes
a parsimonious representation is required, and the results of fitting a regression model
λ̄j(t|H̄i(t)) = Ȳij(t)λ0(t) exp(ψβNi(t−)) gives ψ̂β = 1.41. A similar model was specified
for the death intensities and the Nelson-Aalen estimates plotted in the right panel of
Figure 4.2 reveal increasing risk of death with the occurrence of each event. When the
regression model γ̄j(t|H̄i(t)) = Ȳij(t)γ0(t) exp(ψθNi(t−)) was fit the estimate obtained is
ψ̂θ = 1.36; based on the mortality rate over one year we set γ0 = 0.1. The censoring rate
over the course of a planned study is assumed to be 10% over the 24 months suggesting
ρ = 0.5−1 log(10/9).
Scenario I: Consider the planning of future study aiming to demonstrate that a new
treatment is superior with respect to the occurrence of skeletal complication and superior
with respect to mortality. We suppose that the overall type I error rate is 5% and a
Bonferroni adjustment yields a 2.5% type I error rate for each hypothesis. Suppose two
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two-sided tests are to be conducted, with each at the 2.5% level to control the overall type I
error rate at 5%. Suppose 90% power is required to detect a 20% reduction (βA = log 0.80)
in the risk of recurrent events and a 10% reduction in mortality (θ = log 0.90). We find
minimum sample sizes of 700 and 707 individuals, respectively.
Scenario II: Suppose a non-inferiority design is of interest and we have margins of 50%
for both the recurrent events and death. Suppose the type I error rate for each test is
controlled at 2.5% and 80% power is desired for each test. Suppose the true effect of
treatment corresponds to a 20% loss of the effect of the active control on survival and a
10% loss of effect on the recurrent event outcome. To ensure 80% power to claim non-
inferiority for the survival endpoint, 9052 individuals will be required, and 8506 individuals
will be required for the recurrent event outcome.
4.7 Discussion
This article has provided design criteria for randomized trials with the objective of compar-
ing two treatment groups with respect to the incidence of recurrent events and a terminal
event. The motivating setting involves the palliative treatment of cancer patients with
skeletal metastases who are at risk of both skeletal related events and death. Recurrent
and terminal events arise in many other settings in medical research including transplant
studies in which recipients may experience transient graft rejection episodes and total
graph rejection (Cole et al., 1994). In trials designed to investigate the effect of treat-
ment for advanced chronic obstructive pulmonary disease patients are at risk of recurrent
exacerbations and death (Calverley et al., 2007).
The multistate framework adopted is appealing for modelling such processes because
it structurally incorporates the terminal events as an absorbing state. This is in contrast
to many joint models which incorporate an association between recurrent and terminal
events through shared or correlated random effects arising from parametric models. The
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Figure 4.2: Nelson-Aalen estimates of the cumulative transition intensities for the
placebo group in Hortobagyi et al. (1996).
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proposed analysis represents a compromise between use of intensity-based models reliant
on full model specification and marginal models. The proposed recurrent event model is in
line with the Prentice et al. (1981) approach in which the baseline intensity is stratified on
the cumulative number of events but has the added implicit condition that subjects must be
alive to contribute to the risk set; they are sometimes called “partially” conditional models.
The terminal event state therefore enters in the asymptotic calculations by reducing the
expected size of the risk sets.
The Nelson-Aalen estimates of the cumulative transition intensities and Aalen-Johansen
estimates of the transition probability functions which are estimated under a Markov as-
sumption, are robust in the sense that they remain consistent estimates for non-Markov
processes under independent censoring (Aalen et al., 2001; Datta and Satten, 2001). This
is not true for the estimates of treatment effect in multiplicative intensity-based models
where there is greater reliance on the model assumptions for valid interpretation of co-
variate effects. It would be of interest to study the performance of the separate and joint
tests of treatment effect in this setting, which involve no conditioning on the event history
(Ghosh and Lin, 2000).
Between subject variation in risk of events routinely arises in recurrent event datasets
and mixed Poisson models are often adopted since they account for this heterogeneity. The
marginal intensity of mixed Poisson processes features a sudden change in risk following
event occurrence (Cook and Lawless, 2007). This feature is present in the proposed mul-
tistate framework but the change in risk is not transient. Boher and Cook (2006) showed
empirically that the multistate analysis based on the Prentice et al. (1981) formulation
retains good control of the type I error rate even with naive (i.e., non-robust) variance
estimation, so the multistate partially conditional analysis offers some protection against
heterogeneity.
Mixed models have also been proposed by several authors for modeling the association
between the recurrent and terminal events through correlated or shared random effects
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(Huang and Wang, 2004; Liu et al., 2004; Rondeau et al., 2007). Likelihood and semi-
parametric methods based on estimating functions can be used for analysis of a dataset,
but parametric assumptions could be made to derive required sample sizes. We prefer
the multistate framework however, since the terminal nature of death is reflected in its
designation as an absorbing state. Moreover, with the multistate analysis in which we
adopt time-dependent stratification on the cumulative number of events, our sample size
formula is directly relevant for analyses based on the so-called Prentice-Williams-Peterson
approach (Prentice et al., 1981) to analyze recurrent events in the absence of mortality.
While the multistate framework requires that more parameters be specified, the multiplica-
tive increase in risk with event occurrence is seen in a diverse range of datasets and offers
some degree of parsimony.
We have restricted attention to settings where the event times are at most right cen-
sored. Frequently recurrent events are not observed directly but are only detectable under
careful examination in a clinic. Studies aiming to prevent the occurrence of skeletal metas-
tases involve quarterly examinations of patients at which bone scans are conducted to
assess whether new metastases have developed. The same multistate model can be used
to characterize the incidence of skeletal metastases and death, but the onset times of the
metastases become interval-censored. If the Markov framework remains appropriate, the
methods of Kalbfleisch and Lawless (1985) may be employed with the multistate model
package msm in R/Splus. Sample size calculations must be suitably modified and this is a
topic of ongoing research.
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4.8 Appendix
4.8.1 Asymptotic Equivalence of the Partial Score Statistics
Under the null hypothesis, m−
1













































Using similar arguments in the proofs of Theorem 4.2.1 and 4.3.1 of Gill Gill (1980), one
can show that the second term of the above expression converges in probability to zero as
m→∞ for every β0.
Similarly, let
dMij(u) = dN̄ij(u)− Ȳij(u)eβAvidΛ0j(u)
be the associated martingale process for the recurrent event under the alternative hypoth-








































































Using similar arguments as for the null hypothesis, one can show the second term converges
in probability to zero as m → ∞ for every β0. We now show the last term of the above
expression converges in probability to zero as m → ∞. From the regularity conditions of
Andersen and Gill (1982), the integrand is locally bounded for every u ∈ (0, τ ]. Note that
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j (β0, u) converges almost surely to EA(R
(a)
j (β0, u)) at each time point u, a = 0, 1.
It follows from the Slutsky’s theorem that the first term of the integrand in (4.28) converges












P (Zi(u) = j|Zi(0) = 0, vi = v)P (vi = k)eβAv
and the variance
dΛ20j(u)P (τi > u)
1∑
v=0
P (Zi(u) = j|Zi(0) = 0, vi = v)P (vi = i)e2βAv − µ2
Then, for every u the integrand in (4.28) converges in probability to zero. Therefore,
it follows from the Lebesgue’s dominated convergence theorem that (4.28) converges in
probability to zero as m→∞.
A similar approached can be used to prove the asymptotic equivalence of the partial
score statistics (4.8) is (4.15) under the null hypothesis and (4.17) under the alternative
hypothesis.
4.8.2 Evaluation of Expectations Under the True Model
The necessary expectations require the evaluation of the probability being in state j at
time t, P (Zi(t) = j|Zi(0) = 0), for the proposed Markov process in Figure 4.1. As an
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example, the calculation of E0(Ȳij(u)e
β0vidΛ0j(u)) in (4.11), is carried out as follows,
E0[E0(Ȳij(u)e
β0vidΛ0j(u)|vi)] = E0[eβ0viP (τi > u)P (Zi(u) = j|Zi(u) = 0, vi)]
= P (τi > u)
1∑
v=0
eβ0vP (Zi(t) = j|Zi(0) = 0, vi = v)P (vi = v) .
The transition probabilities are computed as described in the following section.
4.8.3 Evaluation of the Transition Probability Matrix
The evaluation of expectations under particular models requires the calculation of the
Markov transition probability matrix; for notational convenience we suppress the depen-
dence on i. We consider a finite state space with J + 1 states corresponding to the cumu-
lative number of recurrent events from 0 to J and one absorbing state D for the terminal
event. For 0 ≤ s ≤ t, let P (s, t|v) be the (J + 2) × (J + 2) transition probability matrix
with (k, `) entry
Pk,`(s, t|v) = P (Z(t) = `|Z(s) = k, v) , (4.30)
for ` = k + 1 or D, k = 0, 1, . . . , J . Let Qv(t) denote the transition intensity matrix
for individuals in treatment group v, the elements of which are based on the intensities
λk(t|H(t)) and γk(t|H(t)) defined in Section 4.2.
For a time-homogeneous process adopted at the design stage, let λk(t|H(t)) = λk and
γk(t|H(t)) = γk be the intensities for k − 1 → k and k − 1 → D transitions, respectively.
The transition intensity matrix can then be written simply as Qv. and has (k, `) entry
given by λk for k = 1, . . . , J and ` = k + 1, γk for k = 1, . . . , J and ` = J + 2, −(λk + γk)
for k = ` = 1, . . . , J , and zero otherwise. Under such a time-homogeneous Markov model,
P (s, s+ t) = P (0, t) = P (t) and P (t) = exp(Qvt).
There are several approaches available to compute P (t) for a given transition intensity
matrix Qv. If Qv has J + 2 linearly independent eigenvectors, let A be a matrix of eigen-
vectors, and note that AQvA−1 is a diagonal matrix with the eigenvalues d1, d2, . . . , dJ+2 of
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Qv along its diagonal. Then by the spectral value decomposition (Kalbfleisch and Lawless,
1985),
exp(Qvt) = A diag(ed1t, . . . , edJ+2t)A−1 .
If Qv does not have J + 2 linearly independent eigenvectors, the Jordan canonical form
can be used instead (Cox and Miller, 1965). For some nonsingular matrix B, the Jordan
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dk
 (4.31)
is a nk × nk matrix and n1 + n2 + . . .+ np = J + 2. The matrix exponential exp(Qvt) can
be computed (Horn and Johnson, 1994) as
exp(Qvt) = Bf(J )B−1 = Bf(Jk(dk))B−1,
and in this case f(Jk(dk)) takes the form
edkt dke













Numerically, the Jordan decomposition can be obtained through the MATLAB function
jordan for a given Qv and the construction of (4.31) and hence the transition probability
matrix P (t) can be easily computed in MATLAB. Other methods for computing matrix
exponentials are reviewed in Moler and Van Loan (2003). Another numerically stable
approach is the method of scaling and squaring (Moler and Van Loan, 1978), which has
been employed by MATLAB function expm based on an optimal approach (Higham, 2005).
We used this function in sample size calculations for the trial design in cancer metastatic




This thesis has been concerned with statistical methods for the design and analysis of clin-
ical trials involving multiple lifetime events. Specific themes include the use of composite
endpoints (Wu and Cook, 2012a), the issue of event dependent censoring in the analysis
of multivariate failure time data using marginal semiparametric methods (Wu and Cook,
2012b), and sample size calculation for trials involving recurrent and terminal events (Wu
and Cook, 2012c).
A number of additional topics for research have been identified in the process of this
research.
5.1 Asymptotic Properties of Estimates of the Cumu-
lative Hazard Function
In Chapter 3 the asymptotic properties and inference procedures for the regression coef-
ficients in the inverse probability of censoring weighted WLW approach were established.
We proved that the usual sandwich-type robust variance estimator can be adopted when
the weight function is estimated consistently and nonparametrically. It will be interesting
to investigate the asymptotic properties of weighted Nelson-Aalen and weighted Breslow
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estimators for the cumulative hazard function, when the weight function is nonparametri-
cally estimated. Since the Cox partial likelihood is not directed at the inference for these
estimators directly, the method in the proof for the regression coefficients cannot be applied
directly. When the weight function is estimated using semi-parametric regression, Robins
(1993) and Robins and Finkelstein (2000) had established the asymptotic properties of
estimators of cumulative hazard function. In the future, we will investigate the asymptotic
properties and inference procedure for the estimation of cumulative hazard function when
the weight function is nonparametrically estimated to see if there are possible simplifica-
tions.
5.2 Accelerated Failure Time Methods
It is of interest to investigate the use of alternative frameworks for modeling treatment
effects in the context of multivariate failure time data. While the Cox model formulation
is the most commonly adopted when assessing intervention effects in clinical trials, semi-
parametric location-scale models can also be used. It would be interesting to extend the
idea of Wei et al. (1989) to deal with marginal accelerated failure time models with in-
verse probability of censoring weights. More flexible models for the censoring times would
also be of interesting, including additive models of the sort developed by Aalen, or hybrid
Cox-Aalen models (Martinussen and Scheike, 2006).
5.3 Event-Dependent Censoring with Missing Covari-
ates in Multivariate Failure Time Data
The WLW approach is well suited to multivariate failure time data, where each patient is at
the risk of several failure types and may experience each of these failure type once. When
there is event-dependent censoring among multivariate failure times, the naive WLW can
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lead to biased estimations. In Chapter 4 we developed an inverse probability of censoring
weighted WLW to account for the event-dependent censoring. This method is developed
for completed observed covariates information. However, missingness in covariates is a
common problem in survival data analysis for epidemiologic studies. It is well known that
using only completed data in analysis may lead to loss of efficiency and generate biased
estimators. There have been several methods proposed in the literature in univariate
survival data analysis (e.g., Qi, Wang and Prentice (2005)). Although, extending these
existing methods to WLW type of multivariate analysis maybe straightforward, it could
be of interest to investigate new methods when there is event-dependent censoring among
the multivariate failure times with missing covariate.
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Ferreira-González et al. (2008). Composite enpoints in clinical trials. Rev Esp Cardiol,
61(3):283-90.
Fleming, TR and Harrington DP (1991). Counting Processes and Survival Analysis. Hobo-
ken, NJ: Wiley.
109
Fleming TR and Lin DY. (2000). Survival analysis in clinical trials: past developments
and future directions. Biometrics, 56:971-983.
Freemantle N et al. (2003). Composite outcomes in randomized trials: greater precision but
with greater uncertainty? The Journal of the American Medical Association, 289(19):
2545-2575.
Freemantle N, Calvert M. (2007). Weighing the pros and cons for composite outcomes in
clinical trials. Journal of Clinical Epidemiology, 60:658-659.
Freemantle N, Calvert M. (2007). Composite and surrogate outcomes in randomized con-
trolled trials BMJ, 334:756-757.
Gail, M. H., Santner,T. J., and Brown,C. C. (1980). An analysis of comparative carcino-
genesis based on multiple times to experiments tumor. Biometrics, 36(2):255-266.
Genest C and Mackay J. (1986). The Joy of Copulas: Bivariate Distributions with Uniform
Marginals The American Statistician, 40:280-283.
Genest C. (1987). Frank’s family of bivariate distributions. Biometrika, 74:549–550.
Ghosh D, Lin DY. (2000). Nonparametric analysis of recurrent events and death. Biomet-
rics, 56:554–562.
Ghosh, D., Lin, D.Y. (2003). Semiparametric analysis of recurrent events data in the
presence of dependent censoring. Biometrics, 59, 877-885.
Gill, RD (1980). Censoring and Stochastic Integrals (Tract 124), Amsterdam: Mathemat-
ical Center.
George SL, Desu MM (1974). Planning the size and duration of a clinical trial studying
the time to some critical event. Journal of Chronic Diseases, 27:15–24.
110
Greene WF and Cai J. (2004). Measurement error in covariates in the marginal hazards
model for multivariate failure time data. Biometrics, 60:987-996.
Gumbel E. (1960). Distributions des valeurs extremes en plusieurs dimensions. Publ. Inst.
Statist. Univ., 171.
Huang CY, Wang MC (2004). Joint modeling and estimation for recurrent event processes
and failure time data. Journal of the American Statistical Association, 99:1153–1165.
Hallstrom AP, Litwin PE, Weaver WD (1992). A method of assigning scores to the compo-
nents of composite outcome: an example from the MITI trial. Controlled Clinical Trails,
13:148-155.
Higham NJ (2005). The scaling and squaring method for the matrix exponential revisited.
SIAM Journal on Matrix Analysis and Applications, 26:1179–1193.
Hjort NL and Pollard (1993). Asymptotics for minimisers of convex processes. Technical
Report. Department of Statistics, Yale University.
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Sime-
one JF, Seaman J, Knight RD (1996). Efficacy of pamidronate in reducing skeletal com-
plications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia
Breast Cancer Study Group. The New England Journal of Medicine, 335:1785–1791.
Hortobagyi, N. et al. (1998). Long-term prevention of skeletal complications of metastatic
breast cancer with pamidronate. Journal of Clinical Oncology, 16:2038-2044.
Horn RA, Johnson CR (1994). Topics in Matrix Analysis. Cambridge University Press,
Cambridge.
Hougaard P. (2000). Analysis of Multivariate Survival Data. Statistics for Biology and
Health Series, Springer.
111
Hughes, M.D. (1997). Power considerations for clinical trials using multivariate time-to-
event data. Statistics in Medicine, 16:865-882.
Jayaram L et al. (2006). Determining asthma treatment by monitoring sputum cell counts:
effect on exacerbations. European Journal of Respirology, 27:483–494.
Joe, H. (1997). Multivariate Models and Dependence Concepts. Chapman and Hall, London.
Kalbfleisch JD, Lawless JF (1985). The Analysis of Panel Data Under a Markov Assump-
tion. Journal of the American Statistical Association, 80:863–871.
Kalbfleisch, J. D. and Prentice, R. L. (2002). The Statistical Analysis of Failure Time Data.
John Wiley and Sons, Hoboken
Kang, S. and Cai, J. (2009). Marginal Hazards Regression for Retrospective Studies within
Cohort with Possibly Correlated Failure Time Data. Biometrics, 65(2):405–414.
Kaul S and George A (2006). Good Enough: A Primer on the Analysis and Interpretation
of Noninferiority Trials. Annals of Internal Medicine, 145(1):62-69.
Klein,J.P., Keiding, and Kamby,C. (1989). Semiparametric N., Marshall-Olkin Models Ap-
pliedto the Occurrence Metastases Multiple Sites of After Breast Cancer. Biometrics, 45
(4) 1073-1086.
Kallenberg O. (2010). Foundations of Modern Probability. Springer.
Lachin JM, Foulkes MA (1986). Evaluation of sample size and power for analyses of survival
with allowance for non-uniform patient entry, losses to follow-up, non-compliance and
stratification. Biometrics, 42:507–519.
Lawless JF, Nadeau C (1995). Some simple robust methods for the analysis of recurrent
events. Techno- metrics, 37:158–168.
112
Lawless, J.F. (2003). Statistical Models and Methods for Lifetime Data. John Wiley and
Sons.
Lee, EW, Wei, LJ and Amato, D. (1992). Cox-type regression analysis for large numbers
of small groups of correlated failure time observations. In Survival Analysis: State of the
Art, Ed. J.P. Klein and P. K. Goel, pp. 237-47. Dordrecht: Kluwer Academic Publisher.
Li, QH., Lagakos, SW. (1997). Use of the Wei-Lin-Weissfeld method for the analysis of a
recurring and a terminating event. Statistics in Medicine 16, 925-940.
Liang KY et al. (1995). Some recent development for regression analysis of multivariate
failure time data. Life Data Analysis, 1:403-415.
Liang, KY, Self, SG and Chang, YC. (1993). Modelling Marginal Hazards in Multivariate
Failure Time Data. Journal of the Royal Statistical Society. Series B (Methodological),
55(2):441-453.
Liang KY and Zeger SL (1986). Longitudinal data analysis using generalized linear models.
Biometrika, 73:13-22.
Lim Eet al. (2008). Composite outcomes in cardiovascular research: a survey of randomized
trials. Annals of Internal Medicine, 149:612-617.
Lin, DY (1994) Cox regression analysis of multivariate failure time data: the marginal
approach. Statistics in Medicine, 13:2233-2247.
Lin DY, Wei LJ, Yang I, Ying Z (2000). Semiparametric regression for the mean and
rate function of recurrent events. Journal of the Royal Statistical Society: Series B,
69:711–730.
Lin DY, Wei LJ, Ying Z (2001). Semiparametric transformation models for point processes.
Journal of the American Statistical Association, 96:620–628
113
Liu L, Wolfe RA, Huang X (2004). Shared frailty models for recurrent events and a terminal
event. Biometrics, 60:747-756.
Martinussen T and Scheike TH (2006). Dynamic Regression Models for Survival Data.
Springer, New York.
Montori VM, et al., (2005). Validity of composite end points in clinical trials. BMJ,
330:594–596
Moler C, Van Loan C (2003). Nineteen dubious ways to compute the exponential of a
matrix, twenty-five years later. SIAM Review, 45:3-49.
Moler C, Van Loan C (1978). Nineteen dubious ways to compute the exponential of a
matrix. SIAM Review, 20:801-836.
Myles, PS and Devereaux, PJ (2010). Pros and cons of composite endpoints in anesthesia
trials. Anesthesiology, 113(4):776-778.
Neaton JD, Gray G, Zuckerman BD, Konstam M, (2005) Key issues in end point selection
for heart failure trials: composite end points. Journal of Cardiac Failure, 11(8):567-575.
Nelsen, RB (2006). An Introduction to Copulas. Springer, New York.
Newey WK (1994). The Asymptotic Variance of Semiparametric Estimators. Econometrica,
62: 1394-1382.
O’Brien PC (1984). Procedures for comparing samples with multiple endpoints. Biometrics,
40:1079-87.
Piaggio G et al. (2006). Reporting of Noninferiority and Equivalence Randomized Trials.
The Journal of the American Medical Association, 295(10):1152-1160.
114
POISE Study Group. Effects of extended-release metoprolol succinate in patients undergo-
ing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet, 371:1839-
1847.
Prentice, RL and Cai J (1992) Covariance and survivor function estimation using censored
multivariate failure time data. Biometrika, 79(3):495-512.
Prentice RL, Williams BJ, Peterson AV (1981) On the regression analysis of multivariate
failure time data. Biometrika, 68:373-379.
Proschan MA and Waclawiw MA (2000) Practical guidelines for multiplicity adjustment
in clinical trials. Controlled Clinical Trials, 21(6):527-539.
Qi, L, Wang, CY, and Prentice, RL (2005). Weighted estimators for proportional haz-
ards regression with missing covariates. Journal of the American Statistical Association,
100:1250-63.
Robins JM and Rontnitzky A (1992) Recovery of information and adjustment for depenent
censoring usning surrogate markers. AIDS Epidemiology Methodological Issues. Jewell
NP, Dietz K., and Farewell V T. Edit. Birkhauser, Boston.
Robins JM (1993) Information recovery and bias adjustment in proportional hazards re-
gression analysis of randomized trials using surrogate marker. Proceedings of the Bio-
pharmaceutical section, American Statistical Association, 24-33.
Robins JM and Finkelstein DM (2000) Correcting for Noncompliance and Depedent Cen-
soring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW)
Log-Rank Tests. Biometrics, 56:779-788.
Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, Brouste V, Soubeyran P (2007).
Joint frailty models for recurring events and death using maximum penalized likelihood
estimation: application on cancer events. Biostatistics, 8:708-721.
115
Rothmann M et al. (2003). Design and analysis of non-inferiority mortality trials in oncol-
ogy. Statistics in Medicine, 22:239-264.
Sankoh AJ, D’Agostino RB Sr. and Huque MF and Huque MF and Huque MF and Huque
MF (2003). Efficacy endpoint selection and multiplicity adjustment methods in clinical
trials with inherent multiple endpoint issues. Statistics in Medicine, 22(20):3133-3150.
Sheehe PR (2010). Composite end points in clinical trials. Journal of the American Medical
Association, 303:1698.
Schulz, KF and Grimes, DA (2005). Multiplicity in randomized trials 1: endpoints and
treatments. Lancet, 365:1591-1595.
Schoenfeld DA (1983). Sample-size formula for the proportional-hazards regression model.
Biometrics, 39:499-503.
Shorack GR and Wellner JA (1986). Empirical Processes with Applications to Statistics.
SIAM Classics in Applied Mathematics, 2009 Paperback Edition.
Song R, Kosork M R, and Cai J (2008). Robust Covariate-Adjusted Log-Rank Statistics
and Corresponding Sample Size Formula for Recurrent Events Data. Biometrics, 64:741-
750.
Soria JC, Massard C, Le Chevalier T. (2010). Should progression-free survival be the
primary measure of efficacy for advanced NSCLC therapy? Annals of Oncology,
21(12):2324–2332.
Spiekerman CF and Lin DY (1998). Marginal Regression Models for Multivariate Failure
Time Data. Journal of American Statistical Association, 93(443):1164-1175.
Struthers CA and Kalbfleish JD (1986). Misspecified Proportional Hazard Models.
Biometrika, 73:363-369.
116
Therneau T and Grambsch PM (2000). Modeling Survival Data: Extending the Cox Model.
Springer.
Van der Vaart and Wellner J (1996). Weak Convergence and Empirical Processes: With
Applications to Statistics. Springer Series in Statistics. Springer.
Wei, LJ, Lin,DY, and Weissfeld L (1989). Regression Analysis of Multivariate Incomplete
Failure Time Data by Modeling Marginal Distributions. Journal of American Statistical
Association, 84:1065-1073.
Wei LJ and Glidden DV (1997). An overview of statistical methods for multiple failure
time data in clinical trials. Statistics in Medicine, 16:833-839.
White H (1982). Maximum Likelihood Estimation of Misspecified Models. Econometrica,
30:1-25.
Wong WH (1986). Theory of Partial Likelihood. The Annals of Statistics, 14:88-123.
Wu LY and Cook RJ (2012). Misspecification of Cox Regression Models with Composite
Endpoints. Statistics in Medicine, Accepted.
Wu LY and Cook RJ (2012). Marginal Methods for Multivariate Failure Times Under
Event-Dependent Censoring. In preparation.
Wu LY and Cook RJ (2012). The Design of Intervention Trials Involving Recurrent and
Terminal Events. Statistics in Biosciences, Under revision.
Yin G and Cai J (2004). Additive hazards model with multivariate failure time data.
Biometrika, 91(4):801-818.
Yin, G and Cai, J (2005). Quantile regression models with multivariate failure time data.
Biometrics, 61:151-161
117
Yusuf, et al. (2000). Effects of An Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on
Cardiovascular Events in High-Risk Patients. The New England Journal of Medicine,
342(3):145-153.
118
